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ABSTRACT
Dissecting the genetics of Alzheimer’s disease (AD) and Parkinson’s disease 
(PD) has contributed signifi cantly to our understanding of the pathogenesis of 
neurodegeneration in these two complex disorders. For AD, three highly penetrant 
genes (APP, PSEN1 and PSEN2) and one susceptibility gene (APOE) have been 
identifi ed. For PD, seven genes (SNCA, Parkin, UCHL1, NR4A2, DJ1, PINK1 and 
LRRK2) have been found. These genes explain only a small proportion of AD 
and PD patients and are mostly associated with an early onset presentation of the 
disease. APOE remains the only common gene, which increases the risk of both rare 
early and late onset AD. The ongoing challenge is to unravel the genetics of the most 
frequent forms of these complex disorders. In the present paper, we briefl y review 
the state of the art in the genetics of AD and PD. We also discuss the prospects of 
fi nding new genes associated with common forms of these diseases in light of two 
hypotheses concerning the genetic variation of complex diseases: common disease/
common variants and common disease/rare variants.
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INTRODUCTION
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most frequent 
neurodegenerative disorders in western societies and an important cause of disability 
among patients (1, 2). AD and PD are complex diseases in which multiple genes 
as well as environmental factors are involved (1). For both disorders, mutations 
associated with Mendelian forms explain only a small proportion of cases. For AD, 
a common polymorphism also increases the risk. In this paper we review the genes 
that are known to be involved in AD and PD. Further, we discuss approaches to 
identify new genes. 
ALZHEIMER’S DISEASE
AD is the most frequent neurodegenerative disorder and the primary cause of 
dementia in humans. The prevalence of the disease is approximately 1% among 
people aged 65 to 69 years, and increases to nearly 30% by the age of 95 (3). 
Although different risk factors have been associated with the disease, only age and 
a positive history of familial dementia are the risk factors consistently identifi ed in 
different studies (4, 5). In a small proportion of cases, the disease begins before age 
65 years, which is referred to as presenile, or early onset, AD. 
The most important clinical manifestation of AD is the progressive loss 
of cognitive function, short-term memory impairment being one of the fi rst 
manifestations. AD patients gradually lose judgment, visuospatial skills, language, and 
the ability to learn new information. Clinical examination and neuropsychological 
testing combine to make a clinical diagnosis of probable AD, which is confi rmed in 
80-100% of the cases by neuropathology (6). Neuroimaging is not obligatory for the 
diagnosis, but does contribute to the differentiation of AD from other pathologies 
(7). A defi nite diagnosis requires histopathological examination. The pathological 
hallmarks of AD are extra-cellular senile plaques, neurofi brillary tangles, and 
neuronal loss (8). The β amyloid protein is the main constituent of senile plaques, 
whereas neurofi brillary tangles are composed of aggregates of hyperphosphorylated 
tau protein. The neuronal loss occurs in the cortex and the hippocampus, regions 
associated with memory and cognition (9). From a pathological perspective, there is 
no difference between early and late onset forms of AD.
No curative treatment is available for AD. Cholinesterase inhibitors are the 
standard medication to improve cognitive function, but only a small fraction of 
patients respond (10). Other medications alleviate the symptoms associated with late 
stages of AD, but do not halt the progression of the disease.
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Genes and AD
Familial aggregation in AD is strong. This is true for both early and late onset forms 
(11, 12). The fi rst causative gene identifi ed for early onset AD was the amyloid 
precursor protein (APP) gene (see table 1). The APP gene was identifi ed through 
linkage analysis in families segregating an autosomal dominant form of early 
onset AD (13). The APP gene, located at chromosome 21q21.22 (14), encodes 
a transmembrane protein that is normally processed into amyloid fragments. In 
neurons, β and γ secretases cleave the APP protein into smaller amyloid (Aβ) 
peptides. γ secretase cleaves APP into Aβ
40
 and Aβ
42 
fragments. Aβ
42 
has proven to be 
the strongest determinant in the pathogenesis of the disease (15). So far, 18 different 
mutations have been reported in the APP gene in 50 families (http://molgen-www.
uia.ac.be/ADMutations/). All 18 mutations cause amino acid changes in putative sites 
for the cleavage of the APP protein (16). APP mutations are highly penetrant. The 
number of carriers of the various mutations may differ across clinical populations. 
In the general population, not more than 0.5% of early onset AD patients carry a 
mutation in the APP gene (17). Among all AD patients, not more than 0.005% is 
found to carry a mutation in APP. 
Mutations in two other genes have been found to lead to early onset autosomal 
dominant forms of AD (table 1). The presenilin-1 (PSEN1; 14q24.3) and presenilin-2 
(PSEN2; 1q31-q42.3) genes were localized using linkage analysis (18, 19). These 
genes encode proteins that are involved in the normal cleavage of the APP protein, 
increasing the production of Aβ
42
 (20, 21). Indeed, there is convincing evidence 
that PSEN1 encodes a γ secretase (22). A total of 142 mutations have been found 
in PSEN1 in 281 families (http://molgen-www.uia.ac.be/ADMutations/); this makes 
it the gene with the highest number of pathogenic mutations in AD. For PSEN2, 10 
mutations have been found in 16 families. In the general population, mutations in 
the presenilin genes explain about 7.5% of early onset AD (6.5% for PSEN1 and 1% 
for PSEN2). When considering all patients, both early and late onset, sporadic and 
familial cases, the presenilin genes explain less than 0.075% (17) (early onset AD 
represents about 1% of all AD cases).
The fourth gene related to AD is APOE (19q13.32), which was initially identifi ed 
using linkage analysis (23). The relationship between APOE and AD has been 
confi rmed in more than 100 studies conducted in diverse ethnic backgrounds (24). 
The gene has 3 different alleles, APOE*2, APOE*3 and APOE*4. In populations of 
European origin, the allele proportions are 0.08, for APOE*2, 0.77 for APOE*3 and 
0.15 for APOE*4 (17). The APOE*4 allele is the variant associated with AD, and 
unlike the mutations found in APP, PSEN1 and PSEN2, it is not a causal mutation for 
AD. Rather, it is considered to be an allele associated with an increased risk.
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Longitudinal studies in Caucasian populations have shown that carriers of one 
APOE*4 allele have a two-fold increase in the risk for AD (25, 26). The increase 
in risk is higher in homozygotes for the APOE*4 allele; in European and American 
populations the risk can be as high as 8 times that of APOE*3 homozygotes (25, 26). 
The APOE*4 allele is also associated with an earlier onset of the disease (27). The 
shift in the age of onset for carriers of this variant is also dose-dependent in that 
homozygous subjects are affected at earlier ages than heterozygotes for APOE*4. 
Unexpectedly, the progression of the disease does not appear to depend on the 
APOE genotype (28). APOE has also been related to other neurological disorders, 
including cerebral amyloid angiopathy (29), Parkinson’s disease (30) and Creutzfeldt-
Jakob disease (31), and modulates the outcome of other cerebral insults such as 
trauma (29). The APOE gene has also been implicated in the decline of cognitive 
function with age, although study results have been inconsistent (32, 33). 
There is also ample evidence from experimental studies supporting the role of 
APOE in AD. This gene has been implicated in different pathophysiological pathways 
leading to neurodegeneration, including Aβ
42 
deposition and antioxidative stress (34). 
Neuropathological examination of brain tissue in AD patients has shown a higher 
density of neuritic plaques and neurofi brillary tangles in APOE*4 carriers (35, 36). 
Biochemical studies have demonstrated that the APOE gene product, apolipoprotein 
E, can bind both the Aβ
42 
and tau protein (37); this binding appears to be isoform-
specifi c. Transgenic knock-out mice expressing human APOE*4, have an impairment 
in cognitive function and also show neuropathological changes (38, 39). Finally, 
higher levels of APOE expression have been associated with AD in several studies 
(40, 41). However, the exact mechanisms by which the APOE gene increases the risk 
of AD remain to be determined. On the population level, the APOE*4 allele plays an 
important role, explaining up to 17% of all AD patients (table 1).
In summary, all of the genes identifi ed for AD so far, appear to be involved 
in the Aβ
42 
pathway. Most of our insights into the pathogenesis of AD come from 
the relatively rare dominant mutations in the APP and presenilin genes, which, 
essentially, elucidated this pathway. The role of the Aβ
42
 protein is not limited to 
carriers of the APP and presenilin genes. Aβ
42
 metabolism was found to be disturbed 
in sporadic patients without dominant mutations or the APOE*4 allele (42). The 
identifi cation of rare mutations, therefore has not only led to new insights into the 
pathogenesis of familial forms of AD but also shed light on the pathways of sporadic 
forms of the disease.
The genetics of AD is far from being disentangled. It is clear that other genes 
must be involved in AD. The present genes explain less than 20% of all patients, a 
proportion that is for a large part explained by the  APOE*4 allele (table 1). Linkage 
of AD has been shown at chromosomes 1, 4, 6, 9, 10, 12 and 19 (for a recent review 
Luba bw.indd   16 30-08-2006   17:43:50
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of positive linkage analysis see (43) ) (table 2). A recent study suggests that the gene 
responsible for the positive linkage of AD at chromosome 9 is the ubiquilin gene 
(UBQLN1) (44). However, this fi nding remains to be confi rmed by other studies. 
The genes involved in the other regions have not been identifi ed yet. Also, a large 
number of candidate gene studies have been conducted with confl icting results (for 
a review see (45)).
Table 2. Loci identifi ed using linkage analysis for Alzheimer’s disease and Parkinson’s disease
Alzheimer’s disease
References for linkage 
analysis a Candidate genes b
Locus
1p36  (109, 110) MTHFR (111, 112)
4q35 (113, 114) Unknown
5p13-15 (110, 115) Unknown
6p21- 6p35 (110, 113, 116)
TNF-A (117),HLA2 (118)
ESR-A (119), HFE(120)
9p21/q22 (109, 110, 113, 115) UBQLN1(44) , VLDR-R (121)
10q21-22/ 10q24-25 (109, 110, 113, 114)
IDE (122), CDC2 (123), GST1/2 
(124),
12p11 (109, 110, 125) A2M (126),LRP (127)
 Xp11-21/Xq21-26 (109, 110, 113) MAOA (128)
Parkinson’s disease
2p13 (129, 130) PARK3 (SPR) (131)
1p36 (132) PARK9 (Unknown)
1p32 (114, 133) PARK10 (Unknown)
 2q36-37 (134, 135) PARK11 (Unknown)
These loci have been reported at least in two studies although overlapping samples may occur in some of them with the exception of PARK-9 a.
Candidate genes tested within loci b.
PARKINSON’S DISEASE
PD is the second most frequent neurodegenerative disorder in the elderly and the 
most common movement disorder. As with AD, age is one of the strongest risk 
factors associated with this disease. The prevalence of PD is about 0.5-1% among 
people aged 65-69 years and increases to 1-3% in people 85 years old (46, 47). The 
age of onset of PD has a wide distribution. The disease onset can be classifi ed as 
juvenile (onset < 21 years), early (onset between 21 and 50 years) and late onset PD 
(onset > 50 years) (48). Besides age, several environmental factors, such as 1 methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and pesticides, can lead to Parkinsonism 
(49). The relationship with MPTP intoxication, as well as the weak evidence for 
familial clustering, have fuelled a long term dispute on the genetics of PD (50). 
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The main clinical feature of PD is severe motor impairment. The cardinal signs 
are resting tremor, rigidity, bradykinesia, and postural imbalance. Pathological 
changes in the brain are neuronal loss in the dopaminergic system, including the 
substantia nigra pars compacta, the brain stem, the autonomic nervous system, some 
regions in the basal ganglia, and the cortex. Histopathological fi ndings also show 
Lewy body inclusions in the neurons and the dendrites (46).
Treatment for PD that prevents neuronal death progression in the dopaminergic 
system is not yet available. Current therapy is targeted towards improving motor 
and psychiatric symptoms (51). Levodopa continues to be the key medication, as it 
is one of the intermediate molecules in the genesis of dopamine (51). Other groups 
of drugs include inhibitors of monoaminooxidase enzyme, dopamine agonists, and 
coenzyme Q
10
,
 
among others (51). New treatments aimed at preventing neuronal 
damage are also under development.
Genes and PD 
Despite weak evidence for the familial aggregation of PD, several genes have been 
identifi ed. The fi rst gene identifi ed was SNCA (PARK1; 4q21-q23), which encodes 
the α-synuclein protein, one of the major constituents of Lewy body inclusions 
(52). Three missense mutations in SNCA have been identifi ed in families segregating 
dominant forms of PD, including one recently reported in a Spanish family (53-55) 
(table 1). Furthermore, duplications and triplications of this gene leading to PD have 
been found (56). These mutations are rare in patients with sporadic and familial PD 
(57, 58). 
Three other genes have been associated with dominant forms of PD. The NR4A2 
(NURR1) gene, which encodes a nuclear transcription-like protein, is involved in 
the generation of dopaminergic neurons (59). The UCHL1 gene, which encodes an 
ubiquitin carboxy-terminal hydrolase L1, is expressed in neurons and has been found 
in Lewy bodies (60). Although these genes are implicated in physiological pathways 
of neuronal function, their actual role as causal genes for PD has not been confi rmed 
(61). The LRRK2 (PARK8; 12q12) gene has been associated with familial and sporadic 
late onset PD (62). The gene encodes dardarin, a 2482 amino acid protein with 
several domains, including a tyrosine-kinase domain. Eight different mutations have 
been identifi ed in this gene (62-65). These mutations might explain up to 5-6% of 
familial PD and 1% of sporadic PD (64). The role of this gene in the pathogenesis of 
PD remains to be investigated.
Also of interest is the large number of recessive mutations found in PD. The 
parkin (PARK2) gene was identifi ed in Japanese families with recessive juvenile 
Parkinsonism (table 1) (66). The gene, located at chromosome 6q25-q27 (67), 
encodes an ubiquitine E-2 protein. More than 70 mutations have been identifi ed in 
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the parkin gene, including point mutations and genomic rearrangements (48, 68) 
(table1). Parkin mutations explain about 50% of familial cases with recessive early 
onset forms of the disease (69) and between 15-20% of sporadic early onset PD (70). 
Contributions of the gene to late onset PD are not clear, but some studies indicated 
that it might be important (71, 72).
Two other genes are associated with recessive forms of familial PD; DJ1 
(PARK7), and PINK1 (PARK6). DJ1 was identifi ed in families derived from a Dutch 
isolated community (73, 74). The gene is located at chromosome 1p36, and encodes 
a 189 amino acid protein, which is expressed in different tissues including brain. The 
function of this protein in the pathogenesis of early onset PD is not known in detail. 
Some studies indicate that the protein might be involved in the cellular response to 
oxidative stress (75). A total of 11 mutations in DJ1 have been identifi ed (75). The 
alterations include single base pair changes as well as large deletions (76-78). The 
frequency of these alterations is estimated to explain 1% of early onset PD. 
The PINK1 gene is located at chromosome 1p35-36 and has been found to 
segregate in families with recessive PD (79, 80). The product of this gene is a 
tyrosine kinase protein that localizes in the mitochondria, suggesting a possible role 
in energy metabolism (81). The function of the protein has not been determined, 
but its location in the mitochondria suggest that the protein might play a role in 
protecting cells from oxidative stress (72). At least 10 different mutations have been 
identifi ed in this gene (81-84) in different populations. PINK1 mutations appear to 
be more frequent than DJ1 in early onset familial PD, but their role in sporadic PD 
seems to be small (84-86).
Like AD, the genetics of PD are still largely unknown. Other genes must 
be involved in the pathogenesis of PD. Some of them have been localized to 
chromosomal regions (61) (table 2), but the causative genes remain to be discovered. 
Candidate genes have also been tested for association with PD with inconsistent 
results.
PERSPECTIVES FOR FINDING NEW GENES IN NEURODEGENERATIVE 
DISORDERS
So far, the dominant and recessive genes that have been identifi ed for PD and AD 
account for a small fraction of all cases. For AD, a common genetic risk factor is 
known (APOE*4), which explains a substantial number of patients, but leaves more 
than 80% of cases undetermined. For the vast proportion of affected individuals, the 
cause of the disease remains unknown.
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To fully understand the pathways involved in AD and PD, we need to be able to 
identify the other genes involved. The best approach to fi nd these genes depends on 
what type of genetic background we expect: (1) a number of common variants, each 
of them with a small genetic relative risk (87) (i.e., APOE*4), or (2) a large number 
of rare mutations with a large impact on the risk of disease (i.e., PSEN1, parkin). 
The fi rst hypothesis, the common variants/common disease hypothesis is, at fi rst 
sight, appealing. For common forms of AD and PD that occur late in life, it is easy to 
envision a common allele with an associated low risk (88). One may even argue that 
neurodegeneration may be the result of multiple interacting genes and environmental 
factors, rather than a mutation with major effects on protein function. These genes 
may have a small effect by themselves, making it diffi cult to identify them (89). To 
explain their high frequencies, we have to assume that such variants were common 
in early human populations, predating the modern expansion of humans (90). These 
common variants are only preserved if natural selection acting upon them is weak, 
which is likely for late onset diseases as they affect individuals after reproductive age 
(88).
If the common disease/common variants hypothesis is true for AD and PD, 
association studies (genome wide or targeting candidate genes, which, a priori, 
are expected to be involved in the disease based on protein function) provide the 
most powerful approach (45, 91). In association studies, the allele proportions 
are basically compared between a series of patients and controls (89). So far, the 
results of implementing this approach have been confl icting for both AD and PD. A 
recent review of late onset AD (92) included 90 studies which tested for association 
with polymorphisms in candidate genes at 55 different loci. Genes located in only 
three regions (6p21, 10q24, 11q23) showed consistent association in more than two 
studies. Nevertheless, negative results for these regions were also reported (92). 
One of the explanations for the failure of association studies relates to the 
fact that multiple common variants may be present in a single gene (allelic 
heterogeneity). When the number is large, association studies will lose power, since 
a very large number of patients and controls are required to detect a small increase 
in genetic risk for each variant (93). However, fl aws in the design of association 
studies might also have contributed to the confl icting results reported in the literature 
(94, 95). Another issue is that most association studies do not consider gene-gene 
interactions, which are expected to be present in complex diseases (96). A single-
locus design might lack the power to detect a marginal increase in risk for an allele 
that depends on the presence of other alleles or genes, or other environmental 
factors (97, 98). Such genetic interactions might be found in a single gene design, 
provided that very large samples are available (98).
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Last, but not least, most association studies have targeted only limited 
polymorphisms in a gene, which account for a small proportion of all 
polymorphisms available in the human genome.
Contrary to the common disease/common variants hypothesis, the common 
disease/rare variants hypothesis predicts that large numbers of rare variants, 
each one with a strong effect on the risk of disease, are responsible for complex 
diseases (93, 99). For late onset disorders such as AD and PD, these mutations 
can be maintained in populations due to the fact that the diseases occur after the 
reproductive period of life (99). The common disease/rare variants hypothesis is 
consistent with the strong aggregation observed in a large number of families with 
multiple AD cases. Such familial aggregation does not fi t the view of a large number 
of genes with small effects. Common variants with a small effect may explain 
familial aggregation in siblings, but not in extended pedigrees involving parents and 
grandparents, which is the pattern often observed in AD (11, 100). For PD, the weak 
familial aggregation is still compatible with a large number of recessive forms, which 
might explain patients with sporadic forms of the disease.
Linkage analysis in extended families has been successful in mapping genetic 
variants associated with highly penetrant Mendelian forms of AD and PD (table 1). 
Still, for both AD and PD, there have been examples of linkage studies that were not 
replicated or in which the genes have not been identifi ed (table 2). A major problem 
in the identifi cation of a new rare mutation is that, within a family, multiple genes 
may be involved, hampering the power of linkage analysis (95). Further, to fi nd rare 
variants in a series of patients, one has to sequence a large number of patients.
Rather than being two mutually exclusive hypotheses, both the common disease/
common variants and common disease/rare variants approaches may be correct 
for neurodegenerative disorders such as AD and PD. Particularly, for AD, there are 
mutations with major effects (APP, PSEN1, PSEN2), as well as a common variant with 
a small effect (APOE*4). One may argue that this is also the case for PD, although 
common variants with small effects have not been identifi ed yet. 
DISCUSSION
Due to the progress in dissecting the pathogenic pathways of AD and PD, new 
therapeutic approaches are emerging. In AD, it is becoming clear that the disease is 
the result of the imbalance between the production and degradation of the amyloid 
proteins that accumulate in the brain (101, 102). Therefore, a clear target to develop 
new drugs is the prevention of aggregation of amyloid protein (103). As with AD, 
dissecting the genetics of PD has improved knowledge regarding the pathogenesis of 
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the disease tremendously. The discovery of the SNCA gene led to the identifi cation 
of the α-synuclein pathway. It has been shown that misfolding and oligomerization 
of this protein are associated with neuronal toxicity in the dopaminergic system 
(61). Further genetic research into PD revealed other disease mechanisms, including 
mitochondrial dysfunction, the ubiquitine-proteasome pathway, and oxidative stress. 
These fi ndings open new avenues for developing treatment (61, 104). 
How to further dissect AD and PD? A huge problem is the genetic and 
environmental heterogeneity of complex diseases. An approach to overcome this 
problem is to embed the studies in isolated populations, in which a reduced genetic 
heterogeneity and a more uniform environment are expected (105, 106). 
Linkage analysis is still a powerful tool to map genes associated with 
neurodegenerative diseases in such populations. Since, in isolated populations, 
inbreeding is often increased, they also offer a powerful setting to identify new 
recessive mutations. Until now, most studies have focused on genome screens in 
isolates, but also candidate genes studies may also benefi t from the reduced genetic 
diversity (105). 
An alternative approach may be to study AD and PD not as outcomes, but, 
rather, to use endophenotypes, i.e., intermediate phenotypes involved in the 
disease pathways which are, a priori, expected to be strongly related to a gene 
(107). Typical endophenotypes for AD may be either cognitive function or Aβ
42
 
protein levels in blood or CSF. Indeed, using Aβ
42
 protein levels as an intermediate 
phenotype, linkage of AD to chromosome 10 was found (70). For PD, this may 
involve dopamine pathology for instance, as seen on PET scan. Combining the new 
opportunities offered by developments in genomics with the new approaches in 
phenomics, may open new avenues to dissect complex traits such as AD and PD.
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Genetic factors play a crucial role in the risk and progression of Alzheimer’s disease 
(AD) (1). Considerable progress has been made towards understanding the genetics 
of AD. As presented in chapter 1, four genes (APP, PSEN1, PSEN2 and APOE) have 
been implicated in AD. These genes have been shown to contribute to less than 20% 
of late onset AD. Other genes must be involved in the pathogenesis of the disease, as 
approximately 50% of AD cases are genetic in origin (2). However, the identifi cation of 
other genes underlying the pathogenesis of AD has proven to be diffi cult.
One of the explanations for the failure to identify genes for AD is the 
poor design of many linkage and association studies, that have been largely 
underpowered, both in terms of the number of subjects studied, as well as the 
number of markers used (3). One approach to follow in the near future is to study 
large series of cases and matched controls, which will most likely require large 
multicenter studies (4). Alternative approaches, which are more feasible in the 
short term, are to select a relatively small study group while reducing the genetic 
heterogeneity in AD, and to study intermediate phenotypes (endophenotypes) for 
AD (chapter 1).
Cognitive function is a potential endophenotype for AD. Cognitive impairment 
is an overt manifestation of the disease (5). Furthermore, it has been demonstrated 
that a decline in various cognitive domains occurs before the disease is diagnosed 
(6). There is compelling evidence that the apolipoprotein E (APOE) gene, which 
is related to AD, is also involved in cognitive function (7). Thus, dissecting the 
genetics of cognitive function may shed light on the genetics of AD. The aim of 
this thesis is to study the genetic determinants of cognitive function. To reduce the 
problem of genetic heterogeneity, studies are conducted in a genetically isolated 
Dutch population, embedded in the Genetic Research in Isolated Populations (GRIP) 
program. In chapter 3 of this thesis, the infl uence of both genetic drift and founder 
effects on the genetic make-up of the GRIP population are examined. Specifi cally, 
the question of whether common traits such as AD are genetically less complex in 
the GRIP population is addressed.
In chapter 4 the heritability estimates of specifi c cognitive domains in a sample 
of 2575 subjects from the GRIP population are presented. Sex- and age-specifi c 
heritability estimates and the effects of inbreeding on cognitive function are 
evaluated. In chapter 5, the role of the APOE gene on the variation of cognitive 
domains is investigated. APOE is one of the established determinants of AD. The aim 
of this study is to reveal endophenotypes for AD that are relevant for future research. 
In chapter 6, the role of blood pressure, atherosclerosis and four candidate genes 
for hypertension on different domains of cognitive function is examined. Finally, 
in chapter 7, the results of the thesis are summarized and discussed in a broader 
perspective. 
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ABSTRACT
The genetic make-up of genetically isolated populations may differ from the general 
population as a result of genetic drift and founder effects. We assessed the extent 
of this deviation in a recently isolated population located in the southwest of The 
Netherlands and studied as part of the Genetic Research in Isolated Populations 
(GRIP) program. A gene-dropping experiment was performed in a large pedigree 
from this isolate, assuming different founder frequencies in the population founders 
came from. Allelic frequencies in the last generations of this pedigree were 
estimated. Simulation analysis showed large fl uctuations, as measured by variation 
coeffi cient and suffi cient loss probability, when initial frequencies were lower 
than or equal to 1%. For initial frequencies larger than 1%, the fl uctuations were 
small. We also analyzed mean heterozygosity and allele diversity of 592 markers 
in a random sample from the GRIP population. The results were compared with 
a general population (CEPH sample), old large isolate (Icelandic sample) and 
small-sized population of Talana (Sardinia). GRIP mean heterozygosity and mean 
number of alleles were signifi cantly lower as compared with CEPH and Iceland, but 
much higher when compared with the Talana population. We also concluded that 
the fi ndings from the GRIP population for common variants (>1%) are likely to be 
extendable to other young isolates in Europe, as well as to outbred populations.
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INTRODUCTION
Genetic drift and founder effects are major evolutionary forces that determine the 
fl uctuation in the genetic pool of fi nite populations when the effects of selection and 
migration are neglected. The extent of such effects in a population is determined by 
the population size, dynamics, breeding structure and time elapsed since foundation 
(1). Isolated populations are by defi nition founded by a small sample of individuals, 
and geographical and or cultural barriers have restricted migration and breeding 
with other groups, thereby also restricting genetic infl ux (2). Since not all isolated 
populations exhibit the same genetic structure, the extent of drift and founder effects 
will differ according to their evolutionary history. These differential effects will be 
refl ected in terms of the extent of linkage disequilibrium and genetic diversity.
Association studies are predicted to be a powerful tool to detect common genetic 
variants with small effects (3, 4). However, in outbred populations the genetic and 
environmental heterogeneity is high and thus, large numbers of patients and controls 
are required (5). Power may be increased by conducting such studies in an isolated 
population which exhibit less environmental variation and a more homogeneous 
genetic background (2, 6). Another advantage of isolated populations is that linkage 
disequilibrium can be found over large distances. However, the extent of linkage 
disequilibrium and genetic variability varies among different isolated populations, 
making some of them better suited for gene mapping research than others (3). 
Recently, the necessity to study the evolutionary history of isolated populations to 
optimize the use of gene mapping tools has been stressed (7, 8). The value and 
extent of linkage disequilibrium is an issue of active debate and has been extensively 
analyzed in different demographic contexts (9-12). Another crucial point is that drift 
and founder effects can reduce the genetic variability; in isolated populations allele 
variants may become unique as a joint result of drift and founder effects. That is 
the case in Finland, where hereditary disorders that are highly prevalent but barely 
found elsewhere have been reported (13, 14).
Several studies have addressed the effect of drift in isolated populations (8, 15, 
16). The present analysis was intended to analyze the drift and founder effects in 
a young genetically isolated community in The Netherlands. In a previous study 
(17), the extent of linkage disequilibrium in this isolate was evaluated. Here, 
we assessed to what extent drift and founder effects have reduced the genetic 
variability in this isolated population. We simulated the stochastic process due to 
gamete sampling to measure the change in allelic frequencies using the complete 
genealogical information on a large pedigree belonging to this community. Empirical 
data was also used: the average heterozygosity and mean number of alleles in 592 
markers from subjects derived from this isolate was compared with data available 
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from populations with different demographic histories (a general population, and 
populations of Iceland and Talana).
MATERIALS AND METHODS
Subjects
This study was performed using a pedigree derived from an isolated community, 
studied as part of the Genetic Research in Isolated Populations (GRIP) program. This 
young genetic isolate is located in the southwest of The Netherlands. From historical 
data we know that the population was constituted as a religious isolate in the middle 
of the 18th century by a limited number of founders. The population has remained in 
isolation, with a low rate of immigration, and experienced an exponential increase in 
size in the last century. 
In this population, we recently started the ERF (Erasmus Rucphen Family) cohort 
study. This study is concentrating on unraveling genes underlying quantitative 
trait variation in humans. All participants are screened for many quantitative traits 
related to a set of diseases of interest. At present, we have collected phenotypic 
information on 1053 subjects who comprise the last 4-5 generations of a single 
large pedigree, connecting 9800 individuals. The genealogical information includes 
data on individuals that were living in the isolate from about the middle of the 16th 
century, and extends to the current inhabitants of these communities. We performed 
a gene-drop experiment including all people with genealogical information available 
(back to founders from the 16th century). The study was approved by the Medical 
Ethics Committee of the Erasmus Medical Center, Rotterdam, and written consent was 
obtained from all subjects.
Computer simulations and summary statistics
We used the complete genealogical information of the large pedigree to simulate 
stochastic changes due to drift and founder effects. The program package MGA-
Simulate (http://mga.bionet.nsc.ru) was used for the gene-dropping experiment. This 
program randomly assigns genotypes to founders given the allele frequency in a 
population the founders come from, and assuming Hardy-Weinberg equilibrium. The 
allele transmission in descendants is then simulated. In this analysis, we simulated 
one locus with two alleles. Eight different initial frequencies ranging from 0.01 to 
50 percent were considered. For low initial frequencies (0.01, 0.1% and 1%), 10 000 
simulations were used, for others (2.5, 5, 10, 25 and 50%), 5 000 simulations were 
performed. After each simulation, the frequency of one of the alleles was estimated 
in the last generations of the pedigree that at present are included in ERF study. 
Luba bw.indd   38 30-08-2006   17:44:06
The eff ect of genetic drift in a young genetically isolated population 39
The distribution of allele frequencies for each one of the eight initial frequencies 
was obtained by repeated simulations. The means, median and quintiles of the 
distributions were estimated using S-plus 2000 (18)
Mean heterozygosity and mean number of alleles
We compared the heterozygosity and number of alleles between the Dutch isolate, 
Icelandic (deCode) and CEPH (Centre d’Etude du Polymorphisme Humain) 
populations using 592 Short Tandem Repeat markers typed in all three samples. 
These markers were genotyped in 58 random subjects from the GRIP population 
who participated as controls in a recent study; details are described elsewhere (17). 
The expected heterozygosity for each marker was calculated as: h = 1- H, where H 
is the homozygosity calculated as the sum of the squared frequencies of all alleles 
at one locus (19). The mean number of alleles was estimated by allele counting. 
All markers in the GRIP population were tested for deviation from Hardy-Weinberg 
equilibrium proportions using the library genetics for R program (http://www.
r-project.org). 
Information concerning the mean heterozygosity and number of alleles for 
the CEPH families are available at the Marshfi eld Clinic web page (http://research.
marshfi eldclinic.org/ genetics/ Map_Markers /maps/ IndexMapFrames.html), based 
on 8 families with 28 genotyped founders. The expected heterozygosity and mean 
number of alleles in the Icelandic families (deCode) were calculated (as for the 
GRIP population) from Kong et al. (2002), with 297 founder individuals. We also 
compared mean heterozygosity and mean number of alleles from a subset of 20 
markers on chromosome 19 reported for the Talana population, based on 381 
founders (20). The differences in mean heterozygosity and mean number of alleles 
among the GRIP population, CEPH, deCode and Talana families were tested using a 
non-parametric sign test. Bootstrapping was performed to study the effect of sample 
size on the estimation of the mean number of alleles. We derived 1000 random 
samples, each one of 56 chromosomes for each marker from GRIP and deCode 
families, and calculated the mean number of alleles per locus in all 592 markers. 
For a given marker, an overall mean estimate was obtained from these bootstrapped 
distributions. The estimates were compared with the number of alleles per marker in 
CEPH families using a sign test.
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RESULTS
Description of the pedigree
The genealogical data set we used to do simulations comprised a total of 9800 
individuals with 2296 founders. The maximal number of generations was 23 and the 
proportion of men in this data set was 49%. The last 4-5 generations of this large 
pedigree consist of 1053 individuals who are the participants of the ERF study. Out 
of a total of 1053 individuals, 823 (82%) had an inbreeding coeffi cient larger than 
zero, and 112 (11%) had an inbreeding coeffi cient higher than or equal to 0.016, 
which may correspond to a second cousin marriage. The average inbreeding for all 
individuals was 0.006. 90% of the kinship values of all possible pairs were larger than 
zero. The average kinship value for all the ERF pairs was 0.008, and 0.009 for the 
pairs with kinship values larger than zero. 
Simulations
Figure 1 depicts the distribution of the simulated allele frequencies obtained from 
individuals of the last generations of the pedigree. The median and mean estimates 
of these distributions were similar to the initial values we set for founders (table 1). 
However, the shape of the distribution varied according to the initial frequency being 
skewed towards zero for low initial frequencies (fi gure 1 a-c), meaning that the rare 
alleles have disappeared. For instance, at an initial frequency (P
0
) of 0.01% the allele 
was lost in 95.4% of the simulations (table 1). In contrast, alleles that were common 
in founders (P
0 
>1%) were never eliminated. 
Table 1 also shows that the fl uctuation in allele frequencies was highest for 
very rare alleles, as shown by the coeffi cient of variation. At an initial frequency of 
0.01, the coeffi cient of variation was 12 whereas for an initial frequency of 0.025 it 
was 0.5. The highest initial frequency, 0.5 in founders, corresponded to the lowest 
coeffi cient of variation, 0.09. Thus, the fl uctuation in the allele frequencies in the 
contemporary generations is only considerable for alleles with low initial frequencies.
The results obtained in the simulations were compared with theoretical 
distributions expected under a simplifi ed model. In this model, we assumed that 
generation time is 30 years and consequently 7 generations have passed from 
the foundation of the population. The pedigree data was used to compute the 
number of births in 30-year bins. The harmonic mean of these numbers was used 
to estimate the effective population size, N
e
. These calculations suggest an effective 
size of 725.43. We assumed that the isolation of the population is complete (no 
immigration). Under these assumptions, the probability of loss is given by exp 
{-4N
e
p
0 
/t}= exp {(-414.53p
0
)} and the variance of the allelic frequency distribution is 
given by p
0
(1-p
0
)1-[1-(1/(2N
e
))]t = 0.05p
0
(1-p
0
) (21). The values of the loss probability 
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and standard deviation of the distribution of allelic frequency expected according to 
these formulae are shown in table 1. Though it is clear that these formulas over-
estimate the effects of drift, generally the agreement is good. 
Mean heterozygosity and mean number of alleles
The results obtained with simulations were compared with empirical data. A 
sample of 592 markers from 58 random subjects derived from the GRIP population 
was used to calculate mean heterozygosity and mean number of alleles. There 
was no deviation from Hardy-Weinberg equilibrium proportions. We compared 
mean heterozygosity and mean number of alleles in the GRIP population with 
the information available for 28 founders from 8 CEPH families (http://research.
marshfi eldclinic.org/ genetics/ Map_Markers /maps/IndexMapFrames.html) and 297 
founders from Icelandic families (22). Table 2 shows the expected heterozygosity 
per chromosome calculated for these three groups. Overall, the mean heterozygosity 
calculated over 22 chromosomes was 0.757 (standard error; 0.003), 0.759 (standard 
error; 0.004) and 0.768 (standard error; 0.003) for the GRIP population, deCode 
and CEPH families, respectively. The mean heterozygosity was slightly higher in 
the CEPH families, lowest in the young GRIP population with a small founder size, 
and intermediate for the old Icelandic isolate with a large number of founders. The 
mean difference was tested using the sign test and was signifi cant when the GRIP 
population was compared with the deCode families (p = 0.04) and highly signifi cant 
when the GRIP was tested against the CEPH families (p < 0.0001).
The mean number of alleles genome-wide and per chromosome was also 
calculated. As shown in table 2, the GRIP population had the smallest number of 
alleles (9.799; standard error; 0.116). DeCode families showed the largest allele 
diversity with a mean estimate of 10.059 (standard error; 0.125), whereas for the 
CEPH families the mean value was 9.858 (standard error; 0.139). The differences 
in number of alleles, tested using the sign test, was highly signifi cant for all the 
comparisons among the populations (p value < 0.0001). In addition, the mean 
heterozygosity and mean number of alleles from a subset of 20 markers from 
chromosome 19 reported in the Talana population was also compared (20). The 
mean heterozygosity for this population was 0.685 whereas for the GRIP population 
this value was 0.775. Allele diversity was also lower in the Talana population. The 
differences in heterozygosity and mean number of alleles were statistically signifi cant 
(Sign test p < 0.001).
The largest variability showed by the deCode families may be the result of 
having the largest sample size for this population. To correct for unequal sample 
size we performed 1000 bootstrapping replicates. In each replica we sampled 
from the deCode data the same number of founders as for the CEPH families (28). 
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When using bootstrap, the mean number of alleles was estimated as 7.62. The same 
analysis was performed for GRIP, and the estimate was of 7.24. Differences between 
these bootstrapped estimates and the mean number of alleles in the CEPH families 
were statistically signifi cant (Sign test; p value < 0.0001) 
DISCUSSION 
To analyse the extent of drift and founder effects in a recent genetically isolated 
Dutch population, we used the complete genealogical information of a reconstructed 
pedigree to simulate random changes in allele frequencies. Our study showed that 
the fl uctuation in allele frequencies over generations is small for variants attaining 
high frequencies in a population where the founders of the isolate come from. 
Alleles with an initial frequency higher than 1% are likely to be maintained in 
descendants since in our simulation they were never lost. This suggests that common 
alleles that are associated to traits in GRIP will also be found in other outbred 
Dutch populations. In contrast, at frequencies lower than or equal to 1%, alleles are 
often eliminated from our population (probability of loss was as high as 96% for 
initial frequencies equal to 0.01%). These results agree with the results obtained by 
analytical formulas under simplifi ed assumptions. However, the probability of loss is 
higher for the expected distributions, because the assumption of complete isolation 
is not fulfi lled in this isolate.
The fi ndings obtained in the simulation analysis were supported by empirical 
data. Populations with a small effective number of founders are expected to show 
reduced genetic variability as compared to populations with larger founder size and 
genetic fl ow (19). We compared genetic variability in our isolate with populations 
with a different demographic history. CEPH families might be regarded as pedigrees 
derived from an outbred population with a heterogeneous genetic background 
(23). On the other hand, families from Iceland are considered to be a genetically 
homogeneous sample of an old isolated population with a large number of founders 
(24). We found lower allele diversity in our GRIP population than in both the 
CEPH and Icelandic populations. However the difference was not very large. The 
comparison with the Talana population, with a founder size of 200 and a long 
history of geographic isolation (25), showed that allele diversity is lower in Talana 
as compared to the GRIP population. Therefore, genetic variability in our isolate 
seems to lie between that of a population with large drift and founder effects (Talana 
population) and a more heterogeneous one (CEPH families).
In our study, the allele diversity in the deCode families was larger when 
compared with the CEPH families (table 1); theoretically, there are two explanations 
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for this observation. First, the difference in the number of alleles may indicate a 
difference in laboratory techniques applied. Second, the estimated number of alleles 
may be affected by the sample size. As shown by our bootstrapping experiment, 
the second hypothesis is the most likely explanation. By bootstrapping, we showed 
that when we used the same number of founders for all the populations, the GRIP 
population had the lowest allele diversity (7.2 alleles), and deCode families the 
second lowest (7.63). The decrease in the number of alleles when a smaller sample 
was considered was on average two, for both the GRIP population and the deCode 
families (from 9.8 to 7.2 in the GRIP sample and from 10.1 to 7.6 in the deCode 
families). Hence, this result refl ects that allele diversity in a population largely 
depends on the sample size, as reported previously (20). 
In a recent study, Aulchenko et al (2004) studied the amount and decay of 
linkage disequilibrium with genetic distance in this Dutch isolated population. The 
study reported a similar extent of linkage disequilibrium to other recent isolates from 
various parts of the world. Furthermore, linkage disequilibrium was found over large 
distances, highlighting the potential of this population to conduct gene mapping. In 
the present analysis we addressed the magnitude of the composite drift and founder 
effects in this isolate. We have shown that the genetic variability is reduced in the 
GRIP population. However, only alleles with a frequency lower than 1% are likely 
to be lost. The major fi nding of the present study is that although fl uctuations in 
allele frequencies may occur in the GRIP population, and other recent isolates in 
the world due to drift and founder effects, genetic variants with a frequency higher 
than 1% are expected to be present in both, young genetic isolates and outbred 
populations. Therefore, fi ndings of genome screens conducted in young isolates may 
be generalized to other demographic contexts.
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ABSTRACT
Although genetic factors infl uence human cognitive function, their contribution to 
the variation in specifi c cognitive domains is less clear. We estimated the heritability 
of different cognitive domains related to Alzheimer’s disease and other dementias in 
2575 subjects from a recent genetically isolated Dutch population. We also studied 
the effects of inbreeding, and examined sex- and age-specifi c genetic effects on 
the variation of cognitive domains. A variance components method was used to 
estimate the heritability of cognitive domains. We estimated sex-specifi c variance 
components in women and men. Age-specifi c genetic effects were estimated in two 
age categories (<50 years and ≥ 50 years).
The heritability of cognitive domains ranged from 10% (recognition) to 36% 
(visuospatial-visuoconstructive abilities). Inbreeding was associated with a small 
but signifi cant decrease in general cognitive ability, visuospatial-visuoconstructive 
abilities and executive function. Age-specifi c genetic effects were found for 
psychomotor speed, phonological fl uency and susceptibility to interference. The 
genetic correlations for these domains were between 0.64 and 0.73, suggesting that 
about 30% of the genetic expression in these domains might be age-group specifi c. 
Although we did not observe a sex-specifi c genetic background modulating cognitive 
domains, we observed differences in the magnitude of genetic and environmental 
effects between sexes in learning and susceptibility to interference. Our fi ndings 
suggest that the genetic contribution to the variation in cognitive function differs 
across specifi c cognitive domains. We also showed that inbreeding and age-specifi c 
genetic effects modulate specifi c cognitive domains.
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INTRODUCTION
Genetic factors have been shown to play a key role in human cognitive variation 
(1-3). The heritability of general cognitive ability has been consistently estimated 
to be approximately 50% (for a review see (2)). There is less agreement about the 
contribution of genetic factors to the variation of specifi c cognitive domains such as 
memory and executive function, which are commonly affected by aging, Alzheimer’s 
disease (AD) and related disorders (4, 5). Heritability estimates range from 21% 
to 60% for memory (6, 7), while heritability estimates for different components of 
executive function vary from 35% to 79% (8, 9). The variability of these estimates 
might be due to the heterogeneity of the study designs (6, 7, 9, 10) and perhaps, 
different ethnic backgrounds (9, 10).
Age is a strong predictor of cognitive variation. Although environment is a major 
determinant of the age-related differences in cognitive function (11), there is also 
evidence that some of the genetic expression of cognitive function is age-specifi c 
(12). Thus, genes determining cognitive function at birth might differ from those that 
modulate cognitive decline during aging. The latter may be of relevance in light of 
current studies of the genetics of late onset AD and related dementias. 
Along with age, sex is also related to the variation in cognitive function. Sexual 
dimorphism has been documented for several cognitive domains, and there is 
evidence that it might be under genetic control (13-16). Sex-specifi c genetic effects 
on the variation of a number of quantitative traits such as lipid levels, glucose 
metabolism, blood pressure and serotonin levels have been reported (17-19). To 
what extent sexual dimorphism in human cognitive variation is due to sex-specifi c 
genetic expression is unclear.
In certain populations inbreeding was found to contribute to the genetic variance 
of general cognitive ability (20). Early studies showed that inbreeding was associated 
with a lower cognitive performance (21). To date, studies addressing the effects of 
inbreeding on specifi c cognitive domains are scarce. The effect of inbreeding on 
specifi c cognitive domains is of interest, since recently, a role for recessive mutations 
in AD in an inbred population was reported (22).
Previously, we studied the heritability for various cognitive domains in 780 
subjects, belonging to a single extended pedigree from a recent genetically isolated 
Dutch population, in relation to cardiovascular risk factors (23). In the present 
analysis, we extend this previous work to include a larger series of 2575 relatives 
to answer whether inbreeding affects specifi c cognitive domains (memory and 
executive function) and whether there are sex- and age-specifi c genetic effects on 
these domains of cognitive function. 
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MATERIALS AND METHODS
Study population
The present study was conducted within the setting of the Erasmus Rucphen 
Family (ERF) study, a family-based study of a recent genetically isolated population 
located in the southwest of The Netherlands (24, 25). The population was founded 
by a limited number of individuals in the 18th century and was characterized by 
minimal immigration until the last few decades. The genealogical database contains 
information about the current inhabitants of this area and their ancestors and 
includes over 80 000 records. For the ERF study, 22 families were selected that had 
at least 5 children baptized in the community church between 1850 and 1900. All 
living descendants of the families and their spouses, aged 18 and older (n = 2906), 
were invited to participate. The recruitment of participants started in June 2002 and 
fi nished in February 2005. The Medical Ethics Committee of the Erasmus Medical 
Center, Rotterdam approved the study.
Neuropsychological assessment
Trained assistants administered a battery of neuropsychological tests on the ERF 
participants (Sleegers et al, in press). Participants with a diagnosis of neurological 
or psychiatric disorders were excluded (n = 47) (Sleegers et al, in press). Five 
neuropsychological tests adapted to the Dutch language were used to evaluate 
different cognitive domains related to neurodegenerative disorders (table 1) (4, 5, 
26), namely: the Dutch version of the auditory verbal learning test (AVLT) (27, 28), 
the trail making test (TMT) (29), the Stroop colour-word test (30, 31), the verbal 
fl uency test (32, 33), and the block design subtest of the Wechsler adult intelligence 
test (WAIS) (34).
AVLT assesses different components of memory through a number of different 
trials (see table 1 for details), yielding several independent measures (35, 36). 
Four measures were derived from this test: short-term or working memory (AVLT-
trial I), learning (AVLT-trials II-V), delayed recall (AVLT-trial VI) and recognition 
(trial-VII). The TMT consists of two tasks. The fi rst task (TMT-A) is used to assess 
psychomotor speed, whereas the second one (TMT-B) evaluates mainly cognitive 
fl exibility (5). The Stroop colour-word test is composed of three tasks. The fi rst two 
tasks (word naming in card I and colour naming in card II) are used to evaluate 
selective attention. The third task measures susceptibility to interference, or the 
ability to inhibit an automatic response (interference task in card III) (35). The verbal 
fl uency test consists of two measures, semantic fl uency and phonological fl uency, 
which are indicators of several cognitive abilities, including the ability to generate 
search strategies to retrieve information (executive function) (35). Here we used 
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the semantic and phonological fl uency tests, along with TMT-B, and card III of the 
Stroop colour-word test, to evaluate executive function. Finally, the block design 
subtest (WAIS) was used to measure visuospatial and visuoconstructive abilities (35). 
As part of the neuropsychological assessment we included the Dutch Adult 
Reading Test (DART), as a measure of general cognitive ability. This test has a high 
correlation with other more extensive tests that measure general cognitive function 
(35). The education level attained by the ERF participants in the Dutch school system 
was determined. We categorized the education level into three groups: elementary 
(8 years or less of full-time education), junior vocational training (8 to 14 years of 
education) and senior vocational or academic training (at least 15 years of full-time 
education) (36, 37).
Statistical analysis
Gender differences between the scores of the cognitive tests were tested with the 
Mann-Whitney U test. Age-quartile differences between the scores of the cognitive 
tests were tested with the Kruskal-Wallis H test. The inbreeding coeffi cients, the 
probability that 2 alleles at the same locus of a person are identical by descent (i.e. 
derived from the same ancestral allele), were computed for all individuals using all 
available genealogical information. The PEDIG package of programs was used for 
this purpose (38). We categorized the levels of inbreeding into quartiles.
We transformed the cognitive tests that were skewed using the natural logarithm 
(for AVLT-trial VII, TMT-A, TMT-B, cards I, II and III of the Stroop colour-word 
test and block design tests) or the square root (for DART). A full pedigree-variance 
components method as implemented in the SOLAR 2.1.2 software package (39) 
was used to estimate both the heritability as well as the effects of inbreeding on 
the cognitive tests. The phenotypic variance of a cognitive test, which refl ects the 
inter-individual variation of an underlying cognitive domain, was partitioned into its 
additive genetic (σ2
G
) and environmental (σ2
E
) variance components (40). Heritability 
was estimated as the ratio of the additive genetic variance to its phenotypic variance: 
h2= σ2
G
 / (σ2
G
 + σ2
E
);
To estimate the heritability of the cognitive tests the following models were used: 
for general cognitive ability we adjusted for age, age2 (to account for non-linear age 
effects), sex, level of education and inbreeding quartiles. For the other cognitive tests 
we included general cognitive ability in addition to the previous covariates to adjust 
for the variance that is common to all cognitive domains (41). The proportion of the 
phenotypic variance of cognitive tests due to covariates as well as general cognitive 
ability was estimated.
To evaluate sex-specifi c genetic effects on the variation of the cognitive tests, 
we used a standard approach (17, 42). In brief, we included the estimation of 
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genetic and environmental variances specifi c for men and women, as well as the 
correlation between genetic components of a cognitive test in men and women 
(ρ
G
). Three different hypotheses were tested: (1) ρ
G
 = 1, which tests whether genes 
infl uencing a cognitive trait in men and women are the same; (2) σ2
G-M
 = σ2
G-F
, which 
tests whether the genetic variance in men is equal to the genetic variance in women; 
and (3) σ2
E-M
 = σ2
E-F
, which tests whether the residual environmental variance of a 
cognitive trait is equal in men and women. Rejection of hypothesis 1 implies that 
a different set of genes contributes to the variation in cognitive traits in men and 
women. Rejection of hypothesis 2 implies that the magnitude of genetic effects on 
the expression of a cognitive trait differs between sexes. Rejection of hypothesis 
3 indicates that the magnitude of environmental effects on the expression of a 
cognitive trait differs between sexes. Likelihood ratio tests (one degree of freedom) 
were used to evaluate the above hypotheses (nested models) against a general one, 
in which all parameters were estimated (43).
To estimate the age-specifi c variance components of the cognitive tests, we split 
the sample into two broad age categories (< 50 years and ≥ 50 years) and followed 
the same approach as for sex-specifi c genetic effects. We selected this cut-off point 
because age-related differences in cognition are substantial above 50 years of age 
(44).
RESULTS
A total of 2575 subjects were phenotyped for specifi c cognitive domains. The age of 
the subjects ranged from 18 to 89 years (median: 48 years; 95% of the distribution: 
20.38 - 75.28 years) and the proportion of men was of 49%. Of these participants, 
82% were inbred (median: 0.002; 95% of the distribution: 0 - 0.02), although less 
than 10% had inbreeding values equal or higher than 1/64 (equivalent to a second 
cousin marriage). The average level of education corresponded to a junior vocational 
training. Six percent of the population (n = 147) had senior vocational or academic 
training.
Table 2 shows the median scores of the cognitive tests by gender. Men 
performed signifi cantly better in the cognitive tests evaluating general cognitive 
ability (DART), visuospatial-visuoconstructive abilities (block design) and verbal 
fl uency (semantic). Women performed signifi cantly better than men in memory-
related tests such as those evaluating learning, delayed recall, selective attention 
(card II of the Stroop colour-word test) and in susceptibility to interference. The 
median score of the test for working memory (AVLT-trial I) was the same for men 
and women, though the range of the distribution was signifi cantly different (range 
Luba bw.indd   55 30-08-2006   17:44:16
56 Chapter 4
Ta
bl
e 2
. M
ed
ian
 sc
or
e (
2.5
th
-9
7.5
th
 pe
rce
nt
ile
s o
f t
he
 di
str
ibu
tio
n)
 of
 th
e c
og
nit
ive
 te
sts
 by
 ge
nd
er
 an
d a
ge
-q
ua
rti
les
 
 G
en
de
r 
 
Ag
e q
ua
rt
ile
s
 
Co
gn
iti
ve
 te
st
s
M
en
 
W
om
en
P 
va
lu
e†
<3
8.
5 y
r
38
.5
- 5
0 y
r
50
.1
- 6
1.
4 y
r
>6
1.
4 y
r
P 
va
lu
e†
†
Du
tch
 Ad
ult
 Re
ad
ing
 Te
st
64
.0 
(1
8.5
-9
2.0
)
60
.0 
(1
6.0
-8
8.0
)
0.
00
1
72
.0 
(4
0.0
- 9
0.0
)
64
.0 
(2
6.0
-9
0.0
)
58
.0 
(1
6.0
-9
0.0
)
46
.0 
(1
0.0
-8
6.0
)
< 
0.
00
1
AV
LT
-tr
ial
 I
4.0
 (1
.0-
8.0
)
4.0
 (1
.0-
8.0
)
< 
0.
00
1
5.0
 (2
.0-
9.0
)
5.0
 (2
.0-
8.0
)
4.0
 (2
.0-
7.0
)
3.0
 (1
.0-
6.0
)
< 
0.
00
1
AV
LT
-tr
ial
s I
I-V
31
.0 
(1
4.0
-4
9.0
)
35
.0 
(1
6.0
-5
1.9
)
< 
0.
00
1
40
.0 
(2
5.0
-5
3.0
)
35
.0 
(1
9.0
-5
1.0
)
31
.0 
(1
8.0
-4
7.0
)
25
.0 
(1
1.0
-4
1.0
)
< 
0.
00
1
AV
LT
-tr
ial
 VI
7.0
 (2
.0-
13
.0)
8.0
 (2
.0-
13
.0)
< 
0.
00
1
9.0
 (4
.0-
14
.0)
8.0
 (3
.0-
13
.0)
7.0
 (2
.0-
12
.0)
5.0
 (1
.0-
10
.0)
< 
0.
00
1
AV
LT
-tr
ial
 VI
I
14
.0 
(8
.15
-1
5.0
)
14
.0 
(9
.0-
15
.0)
< 
0.
00
1
15
.0 
(1
2.0
-1
5.0
)
14
.0 
(1
0.0
-1
5.0
)
14
.0 
(9
.0-
15
.0)
13
.0 
(7
.0-
15
.0)
< 
0.
00
1
Se
m
an
tic
 fl u
en
cy
37
.0 
(1
9.0
-5
8.0
)
36
.0 
(1
7.0
-5
5.0
)
< 
0.
00
1
41
.0 
(2
5.0
-6
0.0
)
38
.0 
(2
2.0
-5
7.0
)
35
.0 
(1
8.0
-5
5.0
)
29
.0 
(1
4.0
-4
8.0
)
< 
0.
00
1
Ph
on
olo
gic
al 
fl u
en
cy
24
.0 
(7
.0-
47
.0)
24
.0 
(7
.0-
47
.0)
0.6
8
29
.0 
(1
3.0
-5
0.0
)
26
.0 
(1
0.0
-4
7.0
)
22
.0 
(7
.0-
46
.0)
18
.0 
(4
.0-
40
.0)
< 
0.
00
1
TM
T-A
*
33
.0 
(1
6.0
-9
3.0
)
34
.0 
(1
7.0
-9
6.0
)
0.2
0
25
.0 
(1
4.0
-4
8.0
)
30
.0 
(1
7.0
-5
9.0
)
38
.0 
(2
0.0
-8
2.0
)
51
.0 
(2
5.0
-1
21
.0)
< 
0.
00
1
TM
T-
B*
83
.0 
(3
5.0
-4
50
.0)
83
.0 
(3
4.0
-4
50
.0)
0.5
0
56
.0 
(2
9.0
-1
33
.0)
74
.0 
(3
6.0
-2
07
.0)
10
0.0
 (4
6.0
-4
50
.0)
14
8.0
 (6
3.0
-4
50
.0)
< 
0.
00
1
Ca
rd
 I*
48
.0 
(3
5.0
-7
9.0
)
48
.0 
(3
5.0
-7
8.0
)
0.6
4
44
.0 
(3
3.0
-6
8.0
)
46
.0 
(3
5.0
-6
9.0
)
50
.0 
(3
8.0
-7
7.0
)
53
.0 
(3
7.0
-8
6.0
)
< 
0.
00
1
Ca
rd
 II*
61
.0 
(4
5.0
-9
3.0
)
59
.00
 (4
2.0
-8
9.0
)
< 
0.
00
1
55
.0 
(4
2.0
-7
6.0
)
57
.0 
(4
3.0
-8
6.0
)
62
.0 
(4
7.0
-8
8.0
)
66
.0 
(4
6.0
-1
06
.0)
< 
0.
00
1
Ca
rd
 III
*
10
0.0
 (6
7.0
-2
00
.2)
97
.0 
(6
2.0
-1
91
.5)
< 
0.
00
1
84
.0 
(6
1.0
-1
28
.0)
92
.0 
(6
4.0
-1
50
.0)
10
6.0
 (7
0.0
-1
77
.0)
12
4.5
 (8
2.0
-2
74
.0)
< 
0.
00
1
Bl
oc
k D
es
ign
27
.0 
(1
0.0
-6
4.0
)
23
.0 
(1
0.0
-6
2.0
)
< 
0.
00
1
41
.50
 (1
2.0
-6
7.0
)
30
.0 
(1
2.0
-6
1.0
)
20
.0 
(1
0.0
-5
2.0
)
16
.0 
(9
.0-
38
.0)
< 
0.
00
1
† p
 va
lue
 fr
om
 M
an
n-
W
hit
ne
y U
 te
st;
 
††
 p 
va
lue
 fr
om
 Kr
us
ka
l W
all
is 
H 
te
st 
Sig
nifi
 ca
nt
 p 
va
lue
s (
p≤
 0.
05
) a
re
 in
 bo
ld
* H
igh
 sc
or
es
 re
pr
es
en
t l
ow
 co
gn
iti
ve
 pe
rfo
rm
an
ce
 (f
or
 ti
m
e d
em
an
din
g t
as
ks
)
Luba bw.indd   56 30-08-2006   17:44:16
The heritability of cognitive function in a young genetically isolated population 57
in women: 0 - 10 recalled words; range in men: 0 - 12 recalled words). The sex 
differences were not statistically signifi cant for phonological fl uency, card I of 
the Stroop colour-word test and TMT. Table 2 also presents the median score of 
cognitive tests by age-quartiles. Statistically signifi cant differences were observed 
for all cognitive tests (Kruskal-Wallis H test; all p values < 0.001). The highest age 
quartile showed the lowest performance in all cognitive tests. 
Table 3 presents the estimated additive heritability of cognitive tests. The 
heritability of general cognitive ability was 49% (95% C.I, 40% - 53%). For 
memory-related components the estimates were between 10% (recognition; AVLT-
trial VII) and 30% (learning; AVLT-trials II-V). For executive function (cognitive 
fl exibility, susceptibility to interference, verbal fl uency) as well as for visuospatial-
visuoconstructive abilities the estimates were approximately 36%. A large proportion 
of the phenotypic variance of the specifi c cognitive domains (from 20 to 50%) was 
explained by age age2, education, general cognitive ability and inbreeding quartiles 
(table 3). General cognitive ability accounted for between 4% and 22% of the 
phenotypic variance of the other cognitive domains with large effects on executive 
function. Table 3 also shows that inbreeding was signifi cantly associated with lower 
performance on the DART, semantic and phonological fl uency, TMT and block 
design tests. 
Table 4 presents the results of the sex-specifi c variance components analysis. 
The genetic correlations of the cognitive tests between men and women were high 
and did not signifi cantly differ from one (all p values > 0.10). Table 4 also shows 
that women displayed higher genetic variances in learning (AVLT trial II-V; p value 
= 0.02) and in susceptibility to interference (card III of the Stroop colour-word 
test; p value < 0.02), while men exhibit higher environmental variances for these 
domains (p value = 0.03 for learning; p value = 0.02 for susceptibility interference). 
The differences in the components of the variances led to substantially different 
heritability estimates: 40% in women versus 19% in men for learning, and 50% in 
women versus 15% in men for susceptibility to interference.
Age-specifi c variance components were estimated for two broad age groups 
(< 50 years and ≥ 50 years). As shown in table 5, genetic correlations were 
signifi cantly smaller than one in psychomotor speed (TMT-A; p value = 0.03) and 
phonological fl uency (p value = 0.01), and borderline signifi cant in susceptibility to 
interference (card III of the Stroop colour-word test; p value = 0.06). The genetic 
variance was signifi cantly higher in the old age group (50 years and above) for 
general cognitive ability (DART; p value < 0.001) although the genetic correlation 
was not signifi cantly different from one. Likewise, we observed higher genetic 
variances in the advanced age group for almost all specifi c cognitive domains. Only 
in cognitive fl exibility was this difference signifi cant (TMT-B; p value = 0.026). Of 
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interest, the genetic variance of the block design test was not signifi cant for the 
advanced age group, which suggests that the signifi cant heritability estimate we 
observed when considering the whole sample was mainly driven by the young age 
group. The environmental variances were signifi cantly higher in the advanced age 
group in general cognitive ability as well as in verbal fl uency (semantic), cognitive 
fl exibility (TMT-B), recognition (AVLT-trial VII) and susceptibility interference (card 
III of Stroop colour-word test).
DISCUSSION
In this study we found a heritability estimate of 49% for general cognitive ability. For 
specifi c cognitive domains, we observed a wide variation in the heritability estimates 
(from 11% to 36%) after adjusting for the common variability attributed to general 
cognitive ability. In addition, we found that inbreeding was negatively associated 
with general cognitive ability as well as with visuospatial-visuoconstructive abilities 
(block design), and with various components of executive function, namely: 
cognitive fl exibility (TMT-B) and with lower ability to generate searching strategies 
(semantic and phonological). Furthermore, we did not fi nd evidence for a sex-
specifi c genetic background modulating cognitive domains. However, we observed 
differences in the genetic and environmental variances between men and women 
for learning and susceptibility interference. This indicates that although sharing the 
same set of genes, the magnitude of genetic and non-genetic (environmental) effects 
differs between sexes. In contrast to sex-specifi c genetic effects, our results indicated 
that different genes might be involved in cognitive domains at different ages.
The heritability estimates of general cognitive ability as well as of specifi c 
cognitive domains in our analysis were consistent with previous studies (9, 45). The 
highest estimates of heritability were 30% (95% C.I, 21% - 39%) for learning and 
36% (95% C.I, 27% - 45%) for cognitive fl exibility. Both these estimates are in the 
lower range of those reported by others (21% - 60% for memory and 35% - 79% for 
executive function) (46). However, some of these studies used twin-based design, 
which may be prone to overestimate heritability when no other sources of familial 
correlations are considered (47). The fact that we used extended families to estimate 
the heritability of cognitive domains and adjusted for general cognitive ability, which 
accounted for up to 22% of the phenotypic variance for some cognitive tests, may 
explain partly why our fi ndings were in the lower range.
In our study, inbreeding was signifi cantly associated with general cognitive 
ability and with specifi c cognitive domains. Although the effects of inbreeding were 
signifi cant, it only accounted for a relatively small proportion of the total variance 
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of the cognitive tests (1% on average, data not shown). Inbreeding results in an 
increased probability of homozygosity for any allele at any loci, which may have 
adverse or benefi cial effects. However, there is evidence that supports an association 
of inbreeding with decline in cognitive function (21). Our results are in line with the 
fi ndings of Morton (1978) who showed that the decrease in cognitive performance 
as a result of inbreeding was due to the effect of recessive alleles (20). Further, our 
fi ndings suggest that the genetic background underlying specifi c cognitive domains is 
constituted, at least partly, by recessive alleles. 
In spite of the recent indications for genetic infl uences on the sexual dimorphism 
in cognitive function from both human and functional animal studies (13-16), we 
could not demonstrate sex-specifi c genetic effects. Although in the crude analysis we 
observed signifi cant gender differences in general cognitive ability and in specifi c 
cognitive domains, these differences were not explained by sex-specifi c genetic 
effects on the variation of both general cognitive ability and specifi c cognitive 
domains between men and women. Thus, other factors may account for the gender-
related differences in cognitive function documented in other studies. However, in 
our study we estimated the net effect of all genes (40), which does not preclude that 
one or several loci are expressed differently between sexes. 
We found evidence for age-specifi c genetic effects on the variation of 
psychomotor speed, phonological fl uency and susceptibility to interference, with 
genetic correlations between 0.64 and 0.73 that were signifi cantly different from one. 
This means that about 30% of the genetic expression in these cognitive domains 
might be age-group specifi c. In addition, signifi cantly higher genetic variances and 
higher heritability estimates were observed in the advanced age group (≥ 50 years) 
for general cognitive ability and as well as for cognitive fl exibility. This is in line 
with the observation of higher heritability estimates in both general cognitive ability 
and other cognitive domains with increasing age (45). These fi ndings suggest that 
age-specifi c genetic expression modulates cognitive function at old age. A possible 
point of concern is that we only considered two broad age groups and therefore we 
might have missed higher differences in cognitive domains between more narrow 
age groups. Given the preponderant role of age as a determinant of variation in 
cognition, these results need confi rmation in other populations.
Genetically isolated populations may exhibit both increased genetic drift and 
inbreeding and thus may deviate in their genetic composition from the general 
population. Moreover, in genetic isolated populations, there is an increased chance 
of loss or fi xation of some genetic variants potentially leading to lower genetic 
diversity and consequently lower heritability. However, in a recent study (24) we 
have shown that the effects of drift are relatively small in our young genetically 
isolated population and that there is a very small chance of losing an allele unless 
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it had a very low frequency in the original population. Thus, our population should 
not deviate much from the general population in its genetic composition and we do 
not expect that our heritability estimates would substantially differ from those in the 
general Dutch population.
In summary, we found signifi cant heritability in cognitive domains after 
adjustment for general cognitive ability. We also provide evidence that inbreeding 
infl uences the variation in specifi c cognitive domains. The results of sex- and age-
specifi c heritability estimation highlight the potential interaction between genes and 
age- and sex-related factors in the expression of cognitive domains. 
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ABSTRACT
 The APOE gene that encodes Apolipoprotein E is a well-established risk factor 
for Alzheimer’s disease (AD). The APOE*4 allele has been shown to have a strong 
correlation with AD-like alterations in the brains of subjects with mild cognitive 
impairment (MCI) and of cognitively intact subjects. Thus far there is no consensus 
about which specifi c early changes in cognitive function are related to APOE*4. 
In the present study, we investigated the association between the APOE*4 allele 
and cognitive function in non-demented subjects to identify the cognitive profi le 
associated with APOE*4. Furthermore, we evaluated whether age and gender 
modulate the effects of the APOE*4 allele on cognitive function. 
Carriers of the APOE*4 allele had lower short-term memory (p = 0.05) and 
cognitive fl exibility (p < 0.001) than non-carriers. These effects were driven by 
subjects of 50 years and older. In this age group we also found a signifi cant 
relationship between APOE*4 and susceptibility to interference (p = 0.04). Gender 
differences in the effects of the APOE*4 allele were also found. APOE*4 carrier 
women had poorer short-term memory and executive function than non-carriers. 
No differences were observed in men. We concluded that APOE*4 contributes to the 
variation of short-term memory and executive function, which might represent early 
changes in cognitive function in AD. The contribution of APOE*4 to these cognitive 
domains is age- and sex-dependent, with effects being pronounced at older age and 
in women. 
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INTRODUCTION
The apolipoprotein E gene, APOE, is a pleiotropic gene, with a large range of effects 
on human traits including lipid metabolism (1), longevity (2) and cognitive function 
(3). Three common alleles of APOE (APOE*2, APOE*3 and APOE*4) that encode 
three different isoforms of the protein (ε-2, ε-3 and ε-4) have been identifi ed. The 
APOE*4 allele is a well-established genetic risk factor for late onset Alzheimer’s 
disease (AD) (4). Although APOE*4 is neither necessary nor suffi cient to cause AD, 
it has been associated with lower cognitive function and with the progression from 
mild cognitive impairment (MCI) to AD (5-7). Neuroimaging studies in subjects with 
MCI (8), as well as in cognitively intact individuals at high risk for AD (9), have 
shown that APOE*4 is correlated with alterations in the brain which are similar to 
those seen in the brains of AD patients (10). 
Therefore, although there is considerable evidence to support a role for APOE*4 
in cognitive decline in non-demented individuals, some important questions 
remain unanswered. Firstly, it is still not clear whether the effect of APOE*4 on 
cognitive function is global or correlates predominantly with specifi c cognitive 
domains (3). Secondly, there is still debate about whether APOE affects cognitive 
function early in life. Most of the studies that found an association between APOE 
and cognition focused on aged individuals (6). There is evidence that cognitive 
decline during ageing is faster in APOE*4 carriers (7), suggesting that this variant 
modulates processes in the brain that lead to neurodegeneration. Animal studies 
have shown that the APOE protein has signifi cant effects on early brain development 
(11), indicating that APOE may also have an impact on early cognitive reserve. 
Nevertheless, it has not yet been shown whether APOE has early effects on cognitive 
function in humans. Thirdly, it has not yet been established whether there are 
gender-specifi c effects of the APOE*4 allele on cognition. There is some evidence for 
gender-specifi c effects of APOE*4 on cognition in relation to AD (12). The infl uence 
of gender on the neuropsychological profi le associated with APOE*4 has only been 
addressed in a few studies, with confl icting results (6, 13).
In the present study we evaluated the effects of the APOE*4 allele on specifi c 
cognitive domains over a wide age-range in participants of a family-based study. 
The main aim was to study the cognitive profi le associated with the APOE*4 allele 
in non-demented subjects. Further, we addressed whether the effect of this variant is 
homogenous across different ages and whether it is modulated by gender.
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MATERIALS AND METHODS
Study population
Subjects were participants of the Erasmus Rucphen family (ERF) study, a family-
based cohort study conducted in a recent genetically isolated population in The 
Netherlands (14, 15). The population was founded in the middle of 18th century 
by approximately 150 people and remained isolated until the last few decades. An 
extensive genealogical database including over 80 000 records is available for this 
population. For the ERF study, 22 families that had at least 5 children baptized in 
the community church between 1850 and 1900 were selected. All living descendants 
of the families and their spouses, aged 18 and older (n = 2906), were invited to 
participate in the ERF study. Thus, participants from the ERF study were selected 
according to genealogical, and not disease, status. The Medical Ethics Committee of 
the Erasmus Medical Center, Rotterdam approved the study. Participants followed 
a standardized protocol that included a medical questionnaire and an interview. 
Subjects were extensively phenotyped for different clinical measures organized 
into cardiovascular, ophthalmologic, cognitive and anthropometrical blocks. The 
recruitment started in June 2002 and fi nished in February 2005. Genotypes for the 
APOE gene for 1024 participants were available at the time of the current study. 
Using the genealogical database we connected all genotyped participants in a single 
large pedigree consisting of 9800 subjects.
Data collection
A battery of neuropsychological tests was administrated to the participants of the 
ERF study. We used the following tests: the Dutch version of the auditory verbal 
learning test (AVLT) (16), the trail making test (TMT) (17), the Stroop colour-word 
test (18), the verbal fl uency test (17) and the block design subtest of the Weschler 
adult intelligence test (WAIS) (19). These tests are widely used to screen for cognitive 
defi cits in AD and other dementias (20) and were chosen to assess cognitive domains 
over a wide age range.
AVLT assesses different aspects of memory through a series of trials (trial I to 
VII) (21). Different scores were derived from AVLT: short-term memory: number 
of correctly recalled words in the fi rst trial (AVLT trial I); learning: sum of correctly 
recalled words from trial II to V (AVLT trials II-V); delayed recall: number of 
correctly recalled words after a 20 minute delay (AVLT trial VI) and recognition: 
number of correctly recognized words from a 30-word list (AVLT trial VII) (21, 22). 
The TMT evaluates psychomotor speed (part A) and cognitive fl exibility (part B) 
(23). The scores were defi ned as time in seconds to complete the task in parts A 
and B separately. The Stroop colour-word test assesses selective attention (reading 
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task in card I; naming colours in card II) and susceptibility to interference (Stroop 
interference in card III) (21). The scores were defi ned as time in seconds to 
complete the task in cards I, II and III separately. The verbal fl uency test consists of 
semantic and phonological fl uency tests that evaluate searching strategies to retrieve 
stored information (21). The scores for verbal fl uency were defi ned as the sum of 
the named words starting with letters D, A, and T (phonological fl uency), and the 
sum of all named animals and professions (semantic fl uency). Cognitive fl exibility 
(TMT-B), susceptibility to interference (Stroop card III) and verbal fl uency are 
measures of executive function (21). The block design subtest assesses visuospatial 
and visuoconstructive abilities (21). This test was scored as the maximum number of 
replicated blocks per time. Furthermore, we assessed the general cognitive ability of 
the participants with the Dutch Adult Reading Test (DART) (21)
The education level attained by the subjects within the Dutch schooling system 
was determined (22). We categorized the highest level of education attained by 
the participants into three groups: elementary education (8 years or less of full-
time education), junior vocational training (8 to 14 years of education) and senior 
vocational or academic training (at least 15 years of full-time education) (22).
Genotyping
Genomic DNA was extracted from whole blood samples obtained at the baseline 
examination, utilizing the salting out method (24). Samples were genotyped for the 
APOE C112R (APOE*4 allele) and APOE R158C (APOE*2 allele) polymorphisms with 
a Taqman allelic discrimination Assay-By-Design (Applied Biosystems, Foster City, 
CA). Primer sequences are available on request. The assays utilized 5 nanograms of 
genomic DNA and 2 microliter reaction volumes. The amplifi cation and extension 
protocol was as follows: an initial activation step of 10 min at 95oC preceded 40 
cycles of denaturation at 95 oC for 15 s. and annealing and extension at 50 oC for 60 
s. Allele-specifi c fl uorescence was then analysed on an ABI Prism 7900HT Sequence 
Detection System with SDS v 2.1 (Applied Biosystems, Foster City, CA).
Statistical analysis
The APOE genotypes were grouped according to the number of APOE*4 alleles, 
namely: zero (2/2, 2/3 and 3/3 genotypes), one (2/4 and 3/4 genotypes) and 
two copies (4/4 genotypes); or as carriers and non-carriers of the APOE*4 allele. 
General characteristics of the study population among the genotypic groups were 
compared using the one-way ANOVA test (normally distributed) or Kruskal-Wallis 
test (not normally distributed) for continuous variables. For dichotomous variables 
we used the chi-square test. These analyses were performed with SPSS V.11.0 (SPSS 
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Inc. Chicago IL). The observed frequencies of the APOE genotypes were tested for 
deviations from Hardy-Weinberg equilibrium proportions using the chi-square test.
Inbreeding coeffi cients were computed based on all available genealogical 
information using PEDIG software (25). As the inbreeding values were not normally 
distributed, we categorized the levels of inbreeding into quartiles, namely: 25th 
percentile: 1.55 x10 –3, 50th percentile: 0.004, and 75th percentile: 0.009.
We evaluated the effects of the APOE*4 allele on cognitive function in subjects 
belonging to a single large pedigree using linear mixed models to allow adjustment 
for family structure. The genotypes were pooled into APOE*4 allele carriers and 
non-carriers assuming a dominant model, which is consistent with the role of this 
variant in cognitive function (6). The models were adjusted for age, age2 (to account 
for non-linear age effects), sex, inbreeding and general cognitive ability (26). Other 
confounders considered were hypertension, atherosclerosis, body mass index 
(BMI), alcohol consumption and smoking. Because of the skewed distributions of 
the AVLT trial VII, TMT-A, TMT-B, cards I, II and III of the Stroop colour-word and 
block design tests, the data were log-transformed to improve normality (log
20
 (100 * 
cognitive test)).
To evaluate whether age and sex modifi ed the effect of the APOE*4 allele 
on cognitive function, we included interaction terms between APOE and two age 
categories (< 50 years and ≥ 50 years). We selected this cut-off point because age-
dependent infl uences on cognitive function are substantial after the age of 50 years 
(27). We also performed a stratifi ed analysis by gender. All analyses were performed 
using the SOLAR software package (28) 
RESULTS
The frequencies of the APOE alleles were 0.05 for the APOE*2 allele, 0.75 for the 
APOE*3 allele and 0.20 for the APOE*4 allele. The allele and genotype distributions 
were in Hardy-Weinberg equilibrium (p = 1.00). Table 1 presents the general 
characteristics of the population by number of APOE*4 alleles. A signifi cant increase 
in serum levels of total cholesterol and triglycerides was observed with increasing 
number of APOE*4 alleles (p ≤ 0.02). 
Table 2 presents the median and the inter-quartile range of the distribution of the 
cognitive tests by APOE genotype, as well as the p values of the adjusted analysis. 
Short-term memory (AVLT trial I) and cognitive fl exibility (TMT-B) were signifi cantly 
associated with APOE*4 in both the crude analysis (AVLT trial I; p = 0.02; TMT-B; 
p = 0.003) and in the analysis adjusted for family structure (AVLT trial I; p = 0.05; 
TMT-B; p < 0.001). Findings for card II of the Stroop colour-word test were not 
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consistent, as this test did not show any signifi cant association with APOE*4 in the 
analysis adjusted for family structure (card II of the Stroop colour-word test; p = 
0.23). The inclusion of other cardiovascular variables did not substantially change the 
association of the APOE*4 allele with the cognitive tests.
APOE was not associated with DART, the test that assesses general cognitive 
ability. Table 3 presents the effects of the APOE*4 allele on the cognitive tests in 
two age categories (< 50 years; ≥ 50 years). Signifi cant interactions were observed 
for cognitive fl exibility (TMT-B; p = 0.001), recognition (AVLT trial VII; p = 0.03) and 
susceptibility to interference (card III of the Stroop colour-word test; p = 0.04). In the 
group of 50 years and older, a signifi cant association between the APOE*4 allele and 
short-term memory (AVLT trial I; p = 0.05), cognitive fl exibility (TMT-B; p < 0.001) 
and susceptibility to interference (card III of the Stroop colour-word test; p = 0.03) 
was found. The effect of the APOE*4 was also stronger for the AVLT trial VII test 
(recognition) in the group of 50 years and older, although the relation to APOE*4 
was not statistically signifi cant in the stratifi ed analysis. None of the cognitive tests 
were signifi cantly associated with the APOE*4 allele in the younger age group.
Table 4 presents the gender-specifi c effects of the APOE genotype on the 
cognitive tests. Signifi cant interactions were observed for learning (AVLT trials II-V; 
p = 0.03), recognition (AVLT trial VII; p = 0.05), semantic fl uency (p = 0.04) and 
cognitive fl exibility (TMT-B; p = 0.04). In the stratifi ed analysis, the APOE*4 effects 
were only signifi cant in the female group. As shown in table 4, the APOE*4 allele 
was signifi cantly associated with lower performance in tests measuring short-term 
memory (AVLT trial I; p = 0.03), cognitive fl exibility (TMT-B; p < 0.001) and 
susceptibility to interference (card III of the Stroop colour-word test; p = 0.04). The 
Table 1. Demographic characteristics and risk factors per APOE genotypes
APOE
Variable 2/2, 3/2, 3/3 (n =646) 4/2, 4/3 (n =307) 4/4 (n =49) P value†
Age (years) 54.1 (15.91) 55.2 (14.21) 51.9 (12.73) 0.31
Inbreeding 0.006 (0.007) 0.007 (0.008) 0.006 (0.006) 0.06
Men (%) 0.40 0.39 0.51 0.50
Body Mass Index (kg/cm2) 0.3 (0.05) 0.3 (0.05) 0.3 (0.04) 0.34
IMT (mm) 0.86 (0.20) 0.88 (0.22) 0.84 (0.20) 0.14
Fasting glucose (mmol/l) 4.79 (1.11) 4.73 (1.07) 4.56 (0.63) 0.36
Cholesterol (mmol/l) 5.50 (1.10) 5.73 (1.19) 5.68 (1.22) 0.02
Triglycerides (mmol/l) 1.35 (0.80) 1.46 (0.77) 1.65 (0.95) 0.02
HDL (mmol/l) 1.29 (0.38) 1.24 (0.32) 1.13 (0.27) <0.001
Values presented are means (standard deviations) or proportions
IMT (common carotid Intima Media Thickness)
HDL (High density lipoproteins)
† p value of 1-way ANOVA test (continuous variables) or chi-square test (proportions)
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Table 3. Eff ects (standard error) of the APOE*4 allele on cognitive tests in two age categories
< 50 years >= 50 years
Cognitive tests APOE*4 †† APOE*4 ††
AVLT-trial I (short-term memory) -0.181 (0.162) -0.253 (0.125)
AVLT-trials II-V (learning) 0.232 (0.785) -0.788 (0.683)
AVLT-trial VI (delayed recall) 0.091 (0.247) -0.189 (0.248)
AVLT-trial VII† (recognition) 0.079 (0.045) -0.105 (0.071)
Semantic fl uency (verbal fl uency) -0.307 (0.986) 0.148 (0.729)
Phonological fl uency (verbal fl uency) 1.490 (0.951) 0.493 (0.840)
TMT-A† (psychomotor speed)* 1.276 (1.114) 0.723 (1.166)
TMT-B† (cognitive fl exibility)* 1.549 (1.331) 7.105 (1.541)
Card I† (selective attention)* -0.442 (0.678) 0.376 (0.629)
Card II† (selective attention)* -0.132 (0.569) 0.960 (0.611)
Card III† (susceptibility to interference)* -0.635 (0.636) 1.769 (0.790)
Block Design† (visuospatial abilities) 0.004 (1.656)  0.520 (1.242)
The values are the regression coeffi  cients of the APOE*4 carriers onto the cognitive tests.
The models were adjusted for age, age2, sex, inbreeding, education, DART and familial structure 
† Log-transformed cognitive tests
†† The genotypes were pooled into APOE*4 non carriers versus carriers of at least one APOE*4 allele
* Positive eff ects correlate with lower performance (time demanding tasks)
Signifi cant eff ects (p-value< 0.05) of the APOE*4 allele are in bold
Table 4. Eff ects (standard error) of the APOE*4 allele on cognitive tests by gender
Men Women
Cognitive tests APOE*4 ††  APOE*4 ††
AVLT-trial I (short-term memory) -0.121 (0.148) -0.276 (0.127)
AVLT-trials II-V (learning) 0.583 (0.786) -1.224 (0.670)
AVLT-trial VI (delayed recall) 0.355 (0.275) -0.301 (0.233)
AVLT-trial VII† (recognition) 0.034 (0.078) -0.062 (0.056)
Semantic fl uency (verbal fl uency) 1.500 (0.937) -1.253 (0.779)
Phonological fl uency (verbal fl uency) 1.705 (0.951) 0.390 (0.867)
TMT-A† (psychomotor speed)* 0.549 (1.299) 1.508 (1.091)
TMT-B† (cognitive fl exibility)* 1.038 (1.713) 6.544 (1.401)
Card I† (selective attention)* -0.649 (0.796) 0.556 (0.572)
Card II† (selective attention)* 0.546 (0.747) 0.513 (0.518)
Card III† (susceptibility to interference)* 0.124 (0.812) 1.396 (0.686)
Block Design† (visuospatial abilities) 1.612 (1.693) -0.284 (1.290)
The values are the regression coeffi  cients of the APOE*4 carriers onto the cognitive tests.
The models were adjusted for age, age2, sex, inbreeding, education, DART and familial structure 
† Log-transformed cognitive tests
†† The genotypes were pooled into APOE*4 non carriers versus carriers of at least one APOE*4 allele
* Positive eff ects correlate with lower performance (time demanding tasks)
Signifi cant eff ects (p-value< 0.05) of the APOE*4 allele are in bold
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effects of the variant on the test that assesses learning were borderline signifi cant 
(AVLT trials II-V; p = 0.07). No signifi cant evidence for associations between the 
APOE*4 allele and the cognitive tests were found in men.
DISCUSSION
In this family-based study, we found signifi cant associations between the APOE*4 
allele and reduced short-term memory and lower cognitive fl exibility. These effects 
were driven by the group of 50 years and older, and were not signifi cant in the 
younger age group. In addition, we found signifi cant gender differences in the 
effects of the APOE*4 allele on these cognitive domains. Female APOE*4 carriers 
performed less well in memory tests than non-carriers, with stronger effects in short-
term memory and borderline differences in learning.
In our study the association between the APOE*4 allele and cognitive function 
was specifi c to short-term memory (and learning in women), and executive function, 
with larger effects on cognitive fl exibility. This is in line with previous studies that 
demonstrated specifi c effects of APOE*4 on memory and executive function (3, 6). 
The lower cognitive performance in both short-term memory and executive function 
in carriers of at least one APOE*4 allele also fi ts with the domains predominantly 
affected in MCI (29). Our fi ndings suggest that both cognitive fl exibility and short-
term memory, as measured by AVLT and TMT-B, might be early markers of the 
cognitive defi cits related to AD-like pathology. 
Most of the studies that have found an association between APOE and cognition 
have focused on aged individuals, and have provided evidence for a role for APOE 
in cognitive decline in APOE*4 carriers (6). Animal studies, however, have shown 
that apolipoprotein E has a role in early brain development (11). We found that 
the effects of the APOE*4 allele were modifi ed by age, with signifi cant effects only 
in the advanced age group (≥ 50 years). We did not fi nd any signifi cant effect of 
the APOE*4 allele in those aged 50 years and younger. The fact that the APOE*4 
allele has little or no effect on cognitive function early in life, whereas it infl uences 
cognitive fl exibility and short-term memory in late life, suggests that APOE*4 is 
related to cognitive decline, rather than cognitive reserve (7, 30). 
It has been shown that the ε-4 isoform of apolipoprotein E is less effective in 
the maintenance of neuronal repair than the other two apolipoprotein E isoforms 
(ε-3 and ε-2) (31). The effect of APOE*4 late in life may be explained by the 
fact that the defi ciency in repair only becomes manifest at advanced age as the 
cumulative damage to the brain that occurs during ageing increases. However, there 
are alternative pathways that may help explain the effects of APOE*4 in late life. 
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Apolipoprotein E is also involved in the oxidative stress response (31), and APOE*4 
carriers might be more susceptible to oxidative damage. The effects of APOE*4 on 
specifi c cognitive domains may be due to the higher susceptibility of neurons to 
oxidative stress in specifi c brain areas such as hippocampus (32, 33).
There is evidence for gender-specifi c effects of APOE on cognitive function (6, 
13). In our analysis, women showed differences in cognitive performance by APOE*4 
status whereas, in men, the effect was less pronounced and non-signifi cant. This is 
line with a previous study that showed higher cognitive decline in female APOE*4 
carriers, especially in executive function (13). A higher cognitive decline in male 
APOE*4 carriers in memory and executive function was found in another study 
(6). However, the small number of APOE*4 women carriers might account for the 
lack of APOE*4 effects in women in this study (6). Our fi ndings are in line with the 
strong effects of APOE*4 on AD found in a previous meta-analysis (12). Moreover, 
more frequent neurodegenerative lesions in the brain of women with AD have been 
reported (34). The fact that the differences between men and women were observed 
in both short-term memory and executive function, both of which are predominantly 
affected in AD, supports the hypothesis that women carriers of APOE*4 may be an 
important high risk group from a clinical and public health perspective.
There is recent interest in fi nding endophenotypes for AD. These are defi ned as 
intermediate phenotypes that are in the pathways leading to a disease, but with a 
simpler genetic architecture than the disease itself (35). Endophenotypes should be 
correlated with the disease, should be heritable and should be associated with the 
disease risk factors in unaffected subjects (10). In previous work, we showed that 
AVLT, TMT and the Stroop colour-word test are highly heritable (26). Here we show 
that APOE*4 contributes to the variance in these tests only in subjects aged 50 years 
and above. These results suggest that these tests may be valuable endophenotypes 
for AD.
In summary, in this cross-sectional study, we showed that the cognitive profi le 
associated with the APOE*4 allele consists of changes in short-term memory 
and executive function. The lower cognitive performance in these domains was 
signifi cant in women and in individuals 50 years and older.
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ABSTRACT
The genetic variation underlying vascular pathology may contribute to lower 
cognitive function. In this study the effects of systolic blood pressure (SBP), diastolic 
blood pressure (DBP), intima media thickness (IMT) and polymorphisms of the 
angiotensinogen (AGT), angiotensin II type 1 receptor (AT1R), α-adducin-1 (ADD1) 
and G-protein β-3 (GNβ3) genes, which have all been associated with vascular 
pathology, were evaluated in relation to cognition. Participants of a family-based 
study were genotyped for the AGT M235T, AT1R C575T, ADD1 G460W and the GNβ3 
rs2301339 G/A polymorphisms. Cognitive function was assessed with a battery of 
neuropsychological tests. The effects of SBP, DBP, IMT and the four genetic variants 
on the cognitive tests were evaluated using linear mixed models. The effect of the 
four genetic variants was evaluated independently as well as by combining the risk 
alleles.
DBP was associated with worse performance in the trail-making test A (TMT-A). 
IMT was associated with lower performance in the Stroop-colour word test and 
semantic fl uency. In contrast, SBP was associated with a better performance in the 
TMT-A and in card II of the Stroop colour-word test. The effects of SBP on TMT-A 
were driven by the group of 55 years and older. Signifi cant effects of the AGT 235T 
allele on recognition were found. In contrast, worse performance in phonological 
fl uency was associated with the AAD1 460W polymorphism, while a poorer 
performance in TMT-B and card III of the Stroop colour-word test were associated 
with the GNβ3 rs2301339 G allele. Moreover, lower performance in tests evaluating 
learning and in susceptibility to interference with an increasing number of risk alleles 
was found. We concluded that vascular factors and genes involved in blood pressure 
regulation contribute to the variation in cognitive function.
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INTRODUCTION
Vascular pathology plays a key role in the development and progression of cognitive 
decline and dementia including Alzheimer’s disease (AD) and vascular dementia (1, 
2). Vascular damage may lead to hypoperfusion and ischaemia, resulting in neuronal 
death (3-5). Hypertension and atherosclerosis are the main causes of vessel damage 
and there is compelling evidence that each contributes to the risk for AD, vascular 
dementia and reduced cognitive function (6-10).
The Renin-Angiotensin Aldosterone System (RAAS) modulates vascular tone and 
water and salt homeostasis (11, 12), and seems to play a role in hypertension and 
atherosclerosis (3). Four genes involved in RAAS are known to be involved in blood 
pressure regulation: the angiotensinogen (AGT) gene (13); the angiotensin II type 1 
receptor (AT1R) gene (14); the G-protein β3 subunit (GNβ3) gene (15, 18) and the 
α-adducin 1 (AAD1) gene. AGT and AT1R are part of the Renin-Angiotensin System. 
GNβ3 and AAD1 are salt-sensitivity genes in the aldosterone pathway (15-17).
In the present analysis we examined to what extent blood pressure, 
atherosclerosis and polymorphisms of the AGT, AT1R, ADD1 and GNβ3 genes 
contribute to cognition. We studied four polymorphisms in the RAAS genes, which 
have been related to blood pressure regulation: G460W of ADD1 (19), the M235T of 
AGT (13), the C573T of AT1R (14) and the rs2301339 G/A of GNβ3.
 MATERIALS AND METHODS
Study population
This study was conducted within the Erasmus Rucphen Family (ERF) study, which 
is embedded in the Genetic Research in Isolated Populations (GRIP) program. 
The ERF study was designed to fi nd genetic determinants of quantitative traits in 
a recent genetically isolated population in The Netherlands (20, 21). An extensive 
genealogical database, including over 80 000 records is available for the GRIP 
population. For the ERF study, 22 families that had at least 5 children baptized in 
the community church between 1850 and 1900 were selected. All living descendants 
of the families and their spouses, aged 18 and older (n = 2906), were invited 
to participate and the study was approved by the Medical Ethics Committee of 
the Erasmus Medical Center, Rotterdam. Participants of the ERF study followed 
a standardized protocol that included a medical questionnaire and an interview. 
Subjects were phenotyped for different clinical measures including cardiovascular, 
ophthalmologic, cognitive and anthropometrical outcomes. The recruitment of 
subjects started in June 2002 and fi nished in February 2005. The present analysis is 
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based on a sample of 1041 participants, from whom genotypic information of the 
four genetic polymorphisms was available. 
Data collection
A battery of neuropsychological tests was administrated to the participants of the 
ERF study. The following neuropsychological tests were chosen to assess different 
cognitive domains over a wide age-range: the Dutch versions of the auditory verbal 
learning test (AVLT) (22), the trail-making test (TMT) (23), the Stroop colour-word 
test (24), the verbal fl uency test (23) and the block design subtest of the Weschler 
Adult Intelligence Test (WAIS) (25).
AVLT assesses different aspects of memory through a series of trials (trial I to 
VII) (26). Different scores were derived from AVLT: short-term memory: number 
of correctly recalled words in the fi rst trial (AVLT trial I); learning: sum of correctly 
recalled words from trial II to V (AVLT trials II-V); delayed recall: number of 
correctly recalled words after a 20 min-delay (AVLT trial VI) and recognition: 
number of correctly recognized words from a 30-words list (AVLT trial VII) (26, 
27). TMT evaluates psychomotor speed (part A) and cognitive fl exibility (part B) 
(28). The scores were defi ned as time in seconds to complete the task in part A 
and B separately. The Stroop colour-word test assesses selective attention (reading 
task in card I; naming colours in card II) and susceptibility to interference (colour 
interference in card III) (26). The scores were defi ned as time in seconds to 
complete the task in cards I, II and III separately. The verbal fl uency test consists of 
semantic and phonological fl uency tests that evaluate searching strategies to retrieve 
stored information (26). The scores for verbal fl uency were defi ned as the sum 
of the named words starting with letters D, A, and T (phonological fl uency), and 
sum of all named animals and professions (semantic fl uency). Cognitive fl exibility 
(TMT-B), susceptibility to interference (card III of the Stroop colour-word test) and 
verbal fl uency are measures of executive function (26). The block design subtest 
assess visuospatial and visuoconstructive abilities (26). This test was scored as the 
maximum number of replicated blocks per time. We used the Dutch Adult Reading 
Test (DART) as a measure of general cognitive ability (26).
 We determined the education level attained by the subjects within the Dutch 
schooling system (27). We categorized the highest level of education attained by 
the participants into three groups: elementary education (8 years or less of full-
time education), junior vocational training (8 to 14 years of education) and senior 
vocational or academic training (at least 15 years of full-time education) (27).
Blood pressure was measured twice in the sitting position from the right upper 
arm with an automated device (OMRON 711, automatic IS; Vernon Hills Illinois, 
USA). The average of the two measurements was used in the analyses. Hypertension 
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was defi ned as mean systolic blood pressure (SBP) ≥ 160 mmHg or diastolic blood 
pressure (DBP) ≥ 100 mmHg or use of antihypertensive medication (29). Common 
carotid intima media thickness (IMT) was measured with a 7.5-MHz linear array 
transducer (ATL Ultra-Mark IV; Advanced Technological Laboratories, Bethell, 
Washington, USA). The conditions and procedures for the IMT assessment have been 
described previously (30).
Genotyping
The genotyping of the ADD1 G460W, the AGT M235T, the AT1R C573T and the GNβ3 
rs2301339 G/A polymorphisms was performed using TaqMan allelic discrimination 
Assays-By-Design (Applied Biosystems, Foster City, CA) . The primer sequences 
used to genotype these polymorphisms are available on request. The assays utilized 
5 nanograms of genomic DNA and 5 microliter reaction volumes. The amplifi cation 
and extension protocol was as follows: an initial activation step of 10 min at 95°C 
preceded 40 cycles of denaturation at 95°C for 15 s. and annealing and extension 
at 50°C for 60 s. Allele-specifi c fl uorescence was then analysed on an ABI Prism 
7900HT Sequence Detection System with SDS v 2.1 (Applied Biosystems, Foster City, 
CA). 
Covariate adjustment and data analysis
The general characteristics of the study population were compared for the total 
sample as well as in two age categories (< 55 years; ≥ 55 years) using either the 
t-test (continuous variables) or chi squared test (categorical variables). Inbreeding 
coeffi cients were computed based on all available genealogical information using 
PEDIG software (31). As the inbreeding values were not distributed normally, we 
categorized these into quartiles.
The observed frequencies of the genotypes were tested for deviations from 
Hardy-Weinberg equilibrium proportions using the chi-square test (one degree of 
freedom). As the participants of the study were connected to a single extended 
pedigree, we used linear mixed models to evaluate the effect of SBP, DBP, IMT and 
genetic variants on the cognitive tests. Linear mixed models allow adjustments for 
family structure to be made. The models were adjusted for age, age2 (to account 
for non-linear age effects), sex, inbreeding, general cognitive ability (DART) and 
anti-hypertensive medication (32). Because of the skewed distribution, the AVLT trial 
VII, TMT-A, TMT-B, block design and cards I, II and III of the Stroop colour-word 
test were log-transformed to improve normality.
Next we evaluated the effect of the polymorphisms in the four blood pressure 
genes on the cognitive tests, based on an earlier analysis (manuscript in preparation). 
Genotypes of the four genes were pooled as follows: GG = 0, GW/WW = 1 for 
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ADD1 (17); MM/MT = 0, TT = 1 for AGT (33); CT/TT = 0 CC = 1 for AT1R and AA 
= 0, AG/GG = 1 for GNβ3. The latter two polymorphisms were pooled based on 
the blood pressure levels in our population (van Rijn MJ et al. 2006, manuscript 
in preparation). To evaluate the effects of the combined genetic polymorphisms, 
a variable was created for additive effects of the risk alleles (0, 1, 2, 3 and 4 risk 
alleles). The models were adjusted for the aforementioned covariates, except for anti-
hypertensive mediation. All analyses were performed using the SOLAR package (34).
RESULTS
All 1041 subjects were connected in a single pedigree consisting of 9800 individuals. 
The general characteristics of the whole study population, as well as of the two 
age categories, are presented in table 1. The mean age of the total population was 
55 years (SD ±15.10). The mean level of inbreeding was signifi cantly higher in the 
group of 55 years and above. Hypertension and atherosclerosis were signifi cantly 
more prevalent in the old age group (p value < 0.001) (table 2). The mean level of 
education was signifi cantly lower in the group of 55 years and above.
Table 2 shows the effects of the vascular risk factors on cognitive function in 
the total sample and in two age categories (< 55 years and ≥ 55years). Overall, 
DBP was signifi cantly associated with a worse performance on the TMT-A test and 
card II of the Stroop colour-word test. In contrast, SBP was signifi cantly associated 
with a better performance in the TMT-A. IMT was signifi cantly related to a worse 
performance in all of the tasks in the Stroop colour-word test (cards I-III), as well as 
to a worse performance on semantic fl uency. In the age-stratifi ed analysis, SBP was 
Table 1. Characteristics of the study population by two age categories
Demographic variables All sample <55 years (n=520) ≥ 55 years (n=521)
Age (years) 54.27 (15.10) 41.77 (9.02) 66.68 (9.01)†
Men (%) 40.8 38.7 41.3
Inbreeding 0.006 (0.007) 0.005 (0.006) 0.007 (0.008)†
University degree or higher (%) 3.5 6.3 1.0†
Systolic blood pressure (mm Hg) 141.44 (21.86) 132.32 (16.72) 152.08 (22.36)†
Diastolic blood pressure (mm Hg) 80.22 (10.09) 78.97 (10.27) 81.64 (9.73)†
Hypertension (%) 49.0 28.5 73.1†
Anti-hypertensive medication use (%) 21.71 10.5 33.0†
Common carotid IMT 0.86 (0.21) 0.74 (0.12) 1.02 (0.19)†
Continuous values are presented as means (SD)
IMT (Carotid Intima Media Thickness)
†p value < 0.05 compared with people older than 55 years
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signifi cantly associated with better performance in both tasks of TMT in the group 
or 55 years and older. IMT was signifi cantly associated with lower performance in 
the Stroop colour-word test (cards I-III) in this age group. In those younger than 55 
years, DBP showed an association with a poorer performance in TMT-A, whereas 
IMT was signifi cantly associated with worse performance in semantic fl uency and the 
Stroop colour-word test.
The genotype frequencies of the AGT M235T, the AT1R C573T, the ADD1 
G460W, and the GNβ3 rs2301339 G/A polymorphisms were in Hardy-Weinberg 
Equilibrium proportions (p value = 0.72 for AGT, p value = 0.30 for AT1R, p value 
= 0.58 for ADD1 and p value = 0.18 for GNβ3). Table 3 presents the effects of the 
polymorphisms of the AGT, AT1R, ADD1 and GNβ3 genes on the cognitive tests. 
The AGT M235T polymorphism was associated with better performance in the AVLT 
trial VII test (recognition task; p value = 0.01). Carriers of at least one AAD1 460W 
allele had a lower performance in phonological fl uency than non-carriers (p value = 
0.04), whereas carriers of the GNβ3 G allele had lower performance in both TMT-B 
(cognitive fl exibility; p value = 0.02) and in card III of the Stroop colour-word test 
(susceptibility to interference; p value = 0.05).
Table 3. Eff ects of four blood pressure genetic polymorphisms of blood pressure genes on cognitive tests
Cognitive tests AGT AT1R AAD1 GNβ3
AVLT-trial I (short-term memory) -0.123 (0.105) 0.014 (0.093) -0.029 (0.092) 0.152 (0.160)
AVLT-trials II- V (learning) -0.635 (0.559) -0.758 (0.504) -0.779 (0.493) -0.740 (0.842)
AVLT- trial VI (delayed recall) -0.022 (0.192) -0.013 (0.173) -0.221 (0.168) -0.150 (0.293)
AVLT- trial VII† (recognition) 0.129 (0.048) 0.060 (0.044) 0.007 (0.042) -0.085 (0.075)
Semantic fl uency (verbal fl uency) 0.041 (0.641) -0.712 (0.584) -0.643 (0.572) 0.756 (0.961)
Phonetic fl uency (verbal fl uency) -0.236 (0.688) 0.188 (0.619) -1.256 (0.608) 0.976 (1.035)
TMT-A† (psychomotor speed)* 0.038 (0.893) -1.134 (0.808) 1.449 (0.791) -0.661 (1.327)
TMT-B† (cognitive fl exibility)* 0.703 (1.160) -0.400 (1.054) 1.749 (1.034) 4.071 (1.746)
Card I† (reading abilities)* 0.475 (0.508) 0.599 (0.460) -0.073 (0.449) -0.298 (0.766)
Card II†(reading abilities)* 0.432 (0.453) -0.064 (0.410) 0.374 (0.403) -0.044 (0.676)
Card III† (susceptibility to interference)* 0.920 (0.561) 0.566 (0.510) 0.420 (0.501) 1.676 (0.841)
Block Design† (visuospatial abilities) 1.089 (1.112) -0.290 (1.000) -0.451 (0.985) 1.165 (1.643)
Values presented are the regression coeffi  cient of the genetic polymorphism (s.e. are in brackets) onto the cognitive tests
AVLT (Auditory verbal learning test)
TMT (Trail Making Test)
†Log-transformed cognitive tests 
All models were adjusted for age, age2, sex, inbreeding, education, DART, antihypertensive medication and family structure
The genotypes were pooled as: AAD1: GG=0, GW/WW =1; AGT: MM/MT =0, TT=1; GNβ3: AA=0, AG/ GG=1; AT1R: TT/TC=0 CC=1
Signifi cant regression coeffi  cients (p value < 0.05) are in bold
* Positive correlation is associated with lower cognitive performance (for time demanding tasks)
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The effects of the combined risk alleles of the four blood pressure genes are 
presented in table 4. There was a trend towards lower performance in all cognitive 
tests with increasing number of risk alleles. There was a signifi cant difference of 
10 words in AVLT trials II-V (learning) when comparing carriers of the four risk 
alleles against non-carriers (learning; p value = 0.007). The difference between 
these groups for the card III of the Stroop colour-word test was also statistically 
signifi cant (susceptibility to interference; p value = 0.02). The effect of the combined 
risk alleles on the TMT-B was borderline signifi cant (cognitive fl exibility; p value 
= 0.06). Further stratifi ed analysis showed that the effect of the combined alleles 
was signifi cant for those younger than 55 years old for AVLT trials II-V (learning; 
p value = 0.007), whereas in the card III of the Stroop colour-word test, the effect 
of the combined alleles was driven mainly by the group of 55 years and older 
(susceptibility to interference; p value = 0.003).
DISCUSSION
In this family-based study, we found that DBP was associated with lower cognitive 
performance in both TMT-A and card II of the Stroop colour-word test. IMT was 
signifi cantly associated with a worse performance in all tasks of the Stroop test 
as well as with semantic fl uency. In contrast, SBP was associated with a better 
performance in TMT-A, and in card II of the Stroop colour-word test. Furthermore, 
the AGT 235T allele was associated with better performance in the recognition task. 
Lower phonological fl uency in carriers of at least one ADD1 460W allele was found 
whereas the GNβ3 A allele was related to a poorer cognitive performance in tests 
evaluating cognitive fl exibility and susceptibility to interference. The combined 
risk alleles of the four genes were signifi cantly associated with lower performance 
in tasks evaluating learning and susceptibility interference. This association was 
borderline signifi cant for cognitive fl exibility.
In this study, most of the cognitive tests were adversely associated with blood 
pressure and atherosclerosis, which is in line with previous studies (8, 35). However, 
SBP was associated with improved performance in TMT-A and TMT-B in those 
aged 55 years and older. The better cognitive performance in those with high SBP 
is counter-intuitive, but in line with a number of epidemiological studies (for a 
review see (36)), suggesting that with aging the brain may become more susceptible 
to hypoperfusion leading to lower cognitive function (5). High SBP may prevent 
hypoperfusion in the brain, thereby improving cognitive function. On the other 
hand, high blood pressure at a young age may lead to cerebral vessel damage, as 
shown by fi ndings in the Framingham study (35).
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This is the fi rst study in which the four RAAS genes involved in blood pressure 
regulation have been evaluated in relation to cognitive function. In this analysis, 
polymorphisms of two genes involved in salt-sensitivity variation, the GNβ3 and 
AAD1 genes, were associated with a poorer performance in tasks evaluating 
executive function (cognitive fl exibility, susceptibility to interference and verbal 
fl uency). When combining all alleles associated with increased blood pressure, there 
was a decrease in the performance in all cognitive tests, but this was statistically 
signifi cant only in the tests evaluating learning and susceptibility to interference. 
The association of the AGT 235T allele with better recognition is unexpected as 
this allele has been associated with higher blood pressure through the effects of 
increased angiotensinogen levels (13). However, angiotensin II has been associated 
with improved memory in several studies (for a review see (12)). A major issue of 
this analysis is that the assumption of the additive effects of the risk alleles might 
not be true, as most of the gene-gene interactions in previous studies are modelled 
assuming multiplicative effects. However, it has been recently suggested that 
modelling gene-gene and gene-environment interactions using an additive scale may 
indeed be of biological relevance (37). 
In our study, multiple tests were conducted with candidate genes. However, 
the polymorphisms we studied were chosen based on previous research, which 
suggested that these polymorphisms are associated with blood pressure variation 
among the participants of our study. Here, we tested whether these specifi c 
polymorphisms were also associated with cognitive function. Our fi ndings of 
association between blood pressure genes and cognitive function seem to contradict 
our earlier study, in which no signifi cant genetic correlations between vascular 
factors and cognitive function were found (32). However, the lack of genetic 
correlation may be explained partly by the small number of subjects studied.
In conclusion, we have shown signifi cant associations between vascular factors 
and the polymorphisms of four blood pressure regulating genes with cognitive 
functions. Polymorphisms of genes involved in salt-sensitivity pathways had 
signifi cant effects on lower executive function. These fi ndings suggest that genes 
involved in blood pressure explain a small proportion of the variation in cognitive 
function. 
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INTRODUCTION
Alzheimer’s disease (AD) is a late-onset neurodegenerative disorder that affl icts more 
than 24 million individuals worldwide (1). It is expected that this number will double 
in the next 20 years (1). Dissecting the genetics of AD is one of the most challenging 
endeavours for researchers in the fi eld of human genetics and genetic epidemiology. 
A major diffi culty in the identifi cation of genes involved in AD pathogenesis is that it 
is a complex disorder. Multiple genes, each with a small effect, interacting with each 
other and with environmental factors, can confer an increased risk for the disease, 
while rare genetic variants with large phenotypic effects can also cause AD. APOE is 
an example of a gene that can confer an increased risk of AD while APP, PSEN1 and 
PSEN2 are examples of genes with rare variants that cause AD.
As a consequence of the complexity of AD, large sample sizes are required in 
order to estimate the multiple parameters describing a complex system. Alternatively, 
one may attempt to study the system in a setting in which the complexity is expected 
to be reduced. 
Studies in genetically isolated populations are an example of a method for 
reducing the genetic complexity of AD. In such populations, the genetic and 
environmental heterogeneity of complex diseases is expected to be reduced. 
Genetically isolated populations have been proven to be a powerful setting for 
fi nding genes for both Mendelian and complex disorders (2, 3). 
Further, it may also be possible to identify a less complex subsystem of a 
complex disease that can be measured as continuous trait, and concentrate on 
elucidating the genetics of this trait. Endophenotypes provide an example of 
subsystems that can reduce the complexity of diseases, which are caused by 
alterations in different biological pathways. Endophenotypes are traits that are in a 
strong causal relationship with the disease of interest, but are more closely associated 
with the genes underlying the disease. Thus, these traits have a less complex genetic 
architecture (4). 
In this thesis the genetic determinants of cognitive function, which is a potential 
endophenotype for AD, were studied in a young genetically isolated population. In 
this chapter the results of the thesis are discussed. In the fi rst section, the advantages 
and disadvantages of using genetically isolated populations to study complex 
diseases are considered. In the second section, the characteristics of potential 
endophenotypes for AD are discussed. In the third and fourth sections, the genetics 
of cognitive function are discussed. In the last section, possible directions for future 
research in this and other populations are discussed.
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GENETIC RESEARCH IN ISOLATED POPULATIONS
A genetically isolated population usually implies a relatively small group of people 
who have a common population history. This history is described by the time since 
foundation or most recent bottleneck, the number of founders, the population 
growth history (whether the population has undergone expansion or not), the rate 
of immigration, and the pattern of marital choice. The interactions between these 
parameters dictate how large founder and drift effects will be and how large the 
extent of linkage disequilibrium (LD) in the population is. 
In any study of a genetically isolated population it is very important to determine 
the magnitude of founder/drift effects and LD in the study population (5). Both 
effects are double-sided. Strong drift and founder effects tend to deviate the genetic 
pool of isolated populations from that of the general population (3). This makes 
isolated populations suited to the identifi cation of rare genetic variants since these 
variants might reach higher frequencies in particular isolates. However, large 
deviations from the allele frequencies found in the general population reduce the 
chance that any fi ndings can be extended to other populations, as these variants can 
become population-specifi c. 
If a very strong LD between markers and a putative disease locus can be 
expected, the marker coverage of the genome required for association studies may 
be sparse compared to that required in the general population. On the other hand, 
high LD may limit the precision of fi ne mapping of a locus region (3). 
In this context, young genetically isolated populations can present a very 
attractive compromise between reduced heterogeneity and extendibility. Such 
populations, like any relatively small genetically isolated population, are expected to 
have a more homogenous environmental background, and should exhibit moderate 
amounts of LD. Yet, these populations may be very similar to the general population, 
except for the frequencies of rare variant alleles.
GRIP population: a young genetically isolated population
The studies described in this thesis have been conducted within the framework 
of the Genetic Research in Isolated Populations (GRIP) program. The study 
population is located in the Southwest of The Netherlands and it is known from 
historical records that the population was founded in the 18th century by a limited 
number of individuals (<400). In this population new genes and mutations were 
identifi ed for disorders such as early-onset Parkinson’s disease (PD) (DJ-1 gene) 
(6) and hereditary hemochromatosis (SLC11A3 gene) (7). In the past three years, 
research has been conducted to clarify the extent of LD in the GRIP population. 
Aulchenko et al, studied the pattern of LD across the whole genome in a sample 
Luba bw.indd   98 30-08-2006   17:44:49
General discussion 99
of 58 unrelated subjects using micro-satellite markers (8). Moderate LD was found. 
The extent of LD was higher than that observed in the general population (UK) but 
lower than in an old, large genetically isolated population (Finland). The degree 
of LD in GRIP was similar to that of other young, genetically isolated populations 
such as in Palau and the Central Valley of Costa Rica. These fi ndings have been 
confi rmed in a more recent study in which a sample of 200 unrelated individuals 
from the GRIP population was analysed. Service et al, studied LD in 12 genetically 
isolated populations, using a dense map of 2486 SNPs covering chromosome 22 (9). 
They have shown that LD in the GRIP population is similar to that in other young, 
genetically isolated populations. For these populations, it was estimated that an 
approximately 30% reduction in the number of SNP markers would still achieve the 
same effi ciency of coverage in a whole genome screen compared to the general 
population. However, the overall magnitude of LD was different across the different 
young isolated populations (9), which highlights the fact that other factors such as 
founder population size, inbreeding and admixture are also major determinants of 
the LD in a given population. 
In chapter 3 of this thesis, genetic drift and founder effects in the GRIP 
population were studied (9). It was shown that drift and founder effects are strong 
only for variants with frequencies lower that 1%. At the same time, common 
genetic variants identifi ed in the GRIP population are likely to be present at similar 
frequencies in the general population. Table 1 presents empirical support for these 
theoretical fi ndings by comparing the frequencies of common variants of three 
genes (APOE, AGT and CETP) in the GRIP population with their frequencies in 
other Caucasian and non-Caucasian populations. The frequencies of these common 
variants in the GRIP population are similar to the frequencies in the general Dutch 
population and other populations of Caucasian origin. In contrast, the frequency 
Table 1. Allele frequencies of the variants genotyped in GRIP compared with Caucasian and non-Caucasian populations
 Population APOE*4 AGT T235 CETP V405
Caucasian    
GRIP 0.20* 0.48* 0.30**
Finland 0.19 (54) 0.46 (55) 0.37 (56)
General Dutch population 0.15 (57) 0.40** 0.32 (58)
Other Caucasian populations 0.14 (54) 0.45 (59) 0.30 (60)
Non-Caucasian    
African descendants 0.31 (54) 0.83 (61) 0.695†
Asia (Japanese-Chinese) 0.117 (54) 0.76 (61) 0.568† 
* This thesis (chapter 5,6)
** Unpublished data
† dbSNP (rs5882; http//www.ncbi.nlm.nih.gov/SNP)
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of the DJ-1 deletion that causes recessive PD was approximately 0.9% in the GRIP 
population. Although mutations in the DJ-1 gene were found in other populations, 
the specifi c deletion was absent (10). These results confi rm that genetic variants 
identifi ed in young isolated populations can be extended to more general contexts, 
provided that they are relatively common (frequency > 1%). 
In conclusion, the GRIP population represents a typical example of a young 
genetically isolated population. Work presented in this thesis shows that the genetic 
composition of the GRIP population does not deviate much from that of the general 
population. 
Gene-mapping in genetically isolated populations
Genetically isolated populations represent a methodological and computational 
challenge to genetic epidemiologists. One of the major issues when conducting 
research in isolated populations is that the probability that 2 alleles at the same locus 
are identical by descent (IBD) is higher than in outbred populations (11). This holds 
both for 2 alleles at the same locus in one individual (inbreeding) and for 2 alleles 
randomly sampled from 2 different individuals (kinship). Considerable caution must 
therefore be taken in the interpretation of any fi ndings in isolated populations using 
current statistical methods (linkage and association studies) (11). 
In standard affected sib-pair methods, which are commonly used to search 
for loci in complex diseases, sibs are expected to have 0, 1 or 2 alleles identical 
by descent (IBD), with probabilities of 0.25, (0 alleles), 0.50 (1 allele) and 0.25 (2 
alleles) (the null hypothesis). In affected sib-pairs analysis, any excess of sharing 
between sibs is considered a signal of linkage (12). When parents are either related 
or inbred, the expected shared IBD probabilities between sibs might increase under 
the null hypothesis, as the expected shared IBD probabilities were derived assuming 
unrelated parents. The probability of false positive linkage fi ndings increases if this 
is not taken into account (12). Likewise, in genetic mapping using dominant models 
and in homozygosity mapping, higher rates of false positive linkage results are 
obtained when not all kinship and/or inbreeding information is used (Fan et al, 2006 
in press). 
Higher kinship and inbreeding also affect the type-1 error in association studies, 
if patients are substantially more closely related than controls (13). The association 
studies of quantitative traits described in chapters 5 and 6 were performed using 
a linear mixed modelling approach that accounted for the complete pedigree 
information, including thousands of individuals and multiple loops. Therefore, it is 
unlikely that the fi ndings in these chapters are due to cryptic relationships between 
individuals in the study population.
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Another problem is the computational burden caused by the complex pedigrees 
derived from isolated populations. The extensive genealogical records that are 
available for some isolated populations reveal that individuals are inter-related 
through multiple connections. These extended pedigrees become too complex 
for linkage analysis using standard computer programs (11). An alternative is to 
decompose these complex pedigrees into smaller pedigrees, although this might 
reduce the power of the study (11) and increase the risk of type-1 errors (Fan et al, 
2006 in press). For association studies there are methods that account for complete 
genealogical information (14), but they require extensive computational time. High 
performance parallel computing provides one option to speed-up the analysis. Faster 
methods, which account for pedigree structure, such as the restricted maximum 
likelihood method are also an alternative. 
ENDOPHENOTYPES FOR ALZHEIMER’S DISEASE AD
Endophenotypes are the intermediate traits that lie in the pathways relating genes 
to diagnostic entities, but have a simpler genetic architecture than the disease itself 
(4, 15). Criteria to describe an endophenotype have been developed in the fi eld of 
psychiatric genetics (4, 15, 16): (i) the endophenotype has to be associated with the 
disease (ii) the endophenotype should be heritable; (iii) the endophenotype should 
manifest in both affected and unaffected individuals and (iv) the endophenotype 
should occur with a higher frequency in relatives of probands than in the general 
population (15, 16). Current endophenotypes for the genetic analysis of AD can 
be grouped into cognitive tests, brain imaging-derived measures and biochemical 
markers (17).
Cognitive tests
AD is characterized by insidious cognitive decline (18). Although patients with 
AD may also exhibit behavioural and motor symptoms, the main feature of AD 
is global cognitive impairment (18). Cognitive defi cits can be assessed using 
neuropsychological tests (18), which have high sensitivity and specifi city to 
differentiate between different dementia subtypes (18, 19). 
Cognitive traits are suitable for genetic analysis. The heritability of general 
cognitive ability has been estimated to be as high as 50% (20), although for other 
specifi c cognitive domains the estimates are lower and vary according to the study 
design and the population studied (chapter 4). Furthermore, lower cognitive function 
is observed in the relatives of AD cases, especially early onset AD (21). 
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An important caveat in using cognitive domains as endophenotypes for genetic 
analysis is that other variables, such as educational achievement, or depression, may 
affect the assessment of cognitive function (22). For this reason, neuropsychological 
assessment might have lower sensitivity and specifi city than neuroimaging to identify 
pre-clinical AD (23). A major advantage of neuropsychological assessment is that it 
is easy to implement by trained personnel and allows evaluation of large numbers of 
individuals.
Neuroimaging
There is evidence that brain volume is an inheritable trait. A high heritability of 
both grey matter (90%) (24) and white matter (87%) (25) was demonstrated by 
using magnetic resonance imaging (MRI) in twins. Signifi cant heritabilities for 
regional brain volumes have also been demonstrated (26). Measures derived from 
neuroimaging studies have been used as endophenotypes for AD (22), as they 
correlated with AD (27). In addition, fi rst-degree relatives of AD cases show a 
higher degree of structural and functional changes in the brain, without any clinical 
manifestation (28). 
A complication when using these quantitative imaging measures is the high 
implementation cost and time as specialized personnel are required to analyse the 
imaging data. Thus far, such studies were based on relatively small sample sizes. 
Developments in neuroimaging may make large-scale studies feasible in the future. 
Biochemical markers
The β-amyloid protein (Aβ) is a key element in the cascade of events that leads to 
AD (29). Increased concentrations of the Aβ
42 
and Aβ
40 
fragments of the Aβ protein in 
blood have been associated with AD in some studies (30, 31). Recently, it has been 
shown that low levels of the Aβ
42 
fragment, together with the levels of tau protein, in 
cerebral-spinal fl uid (CSF) have high sensitivity and specifi city to predict AD (31). Aβ 
levels are heritable, with estimates of 56% for Aβ
42
 levels and 41% for Aβ
40
 levels in 
AD families (32). In addition, several studies have shown that fi rst-degree relatives of 
late onset AD cases are at risk of exhibiting higher levels of Aβ (32). 
One major issue is that the assessment of Aβ
40
 and Aβ
42
 levels in CSF is an 
invasive procedure. Aβ
40
 and Aβ
42 
levels can also be determined in plasma. However, 
the levels of these proteins vary with age and with the levels of serum creatinine, 
and correlate poorly with the levels in CSF (33). In addition, in cross-sectional studies 
a large overlap between the levels on these proteins in AD patients and in controls 
has been found (33). In summary, these endophenotypes await further technical 
development. 
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GENETIC STUDIES OF COGNITIVE FUNCTION
Heritability studies
The classical approach to model the genetic variation of a continuous trait is to 
partition the phenotypic variance (V
P
) of a trait onto its genetic and environmental 
variance components (V
G
 and V
E 
respectively) (34): V
P
 = V
G
 + V
E 
The proportion of phenotypic variance that is explained by genetic factors is 
denominated heritability (34).
Twin studies are often used to estimate heritability (35). In this design, the 
heritability is estimated as twice the difference of the intra-class correlation of 
monozygotic twins minus the intra-class correlation of dizygotic twins (26). The main 
limitation of twin studies is that shared genetic and environmental effects cannot be 
discriminated using only sib-correlations (35). Therefore twin studies tend to give 
infl ated heritability estimates. It has been argued that for cognitive function this does 
not represent a problem, as early shared environmental effects may not infl uence 
cognitive abilities in late life. Yet, it has been shown that non-genetic infl uences may 
have an important contribution to specifi c cognitive domains such as verbal fl uency 
(36). In addition, the assumption of homogenous environmental effects for both 
monozygotic and dizygotic twins might not apply (37). 
The above caveats for the twin studies may be overcome by using adoption 
studies that compare correlations between twins reared apart and adopted children 
with shared environments (35). These studies are powerful in discriminating between 
shared environmental and genetic effects, but they are limited by the scarcity of 
suitable subjects. 
Alternatively, heritability can be also estimated by including other types of 
relatives in the analysis. Distant relatives are not expected to share a common 
environment and therefore studies based on extended pedigrees may provide more 
reliable estimates of heritability. These studies are less discriminative than adoption 
studies, but have the advantage of the availability of large numbers of subjects. 
Heritability estimates range across different populations as well. Differences in 
the heritability estimates for cognitive function have been attributed to differences in 
the genetic background, but even more to differences in the environment. Despite 
these shortcomings, heritability analysis is a powerful method to determine whether 
genes are accounting for a large proportion of the variance of a cognitive trait.
Defi nitions of phenotypes for genetic analysis
Cognition is a composite of multiple, highly correlated cognitive abilities (18). Early 
studies of the variation of psychometric intelligence test results among individuals 
showed that a general factor (general intelligence or “g” factor) explained a large 
Luba bw.indd   103 30-08-2006   17:44:53
104 Chapter 7
proportion of the variation of cognitive tests (38). Furthermore, multivariate genetic 
studies of intelligence have also shown that “g” explains a large proportion of the 
genetic variance of psychometric tests (38). From a genetic perspective, this might 
imply that the genetic make-up of cognitive function is constituted by “general” 
genes that are common to all cognitive domains rather than specifi c genes that affect 
only a single domain (39).
However, cognition is a complex trait. As for other complex traits, the genetic 
architecture of cognition will most likely consist of multiple genes each with a mild 
effect on the expression of human cognitive variation (40). With this assumption 
in mind, it might be more powerful to study the genetics of cognitive function in 
discrete entities, rather than considering cognition a single unit (41), especially if the 
goal is to fi nd genetic and environmental determinants for AD. 
Functional studies have revealed that the APOE variant APOE*4 is associated 
with alterations in the brains of non-demented subjects at high risk for AD (such as 
fi rst-degree relatives or carriers of early-onset AD mutations) that are similar to those 
observed in AD patients (28). Therefore this genetic variant may also be valuable to 
underscore changes in domains of cognition that are stronger correlated with AD and 
its prodromal phases. For example, in chapter 5 of this thesis, the relation between 
APOE and cognitive function was evaluated. The APOE*4 allele was associated with 
a worse performance in cognitive tests measuring short-term memory and executive 
function. There was no effect on other cognitive domains. These results suggest that 
reduced short-term memory and executive function might be early markers for AD 
and therefore potential endophenotypes for genetic studies. 
Other risk factors may have effects on specifi c cognitive domains. For example 
hypertension has been shown to affect executive function (43), whereas visuospatial 
abilities appear not to be affected (44). In chapter 6, the relationships between blood 
pressure and atherosclerosis with cognitive function were studied. Increased blood 
pressure and IMT were associated mainly with lower executive function whereas 
memory-related tests did not show any association. The fi ndings presented in 
chapter 5 and 6 demonstrate that cognitive domains are differentially affected when 
comparing the APOE*4-related spectrum (typical from AD) and hypertension-related 
spectrum (typical of vascular dementia).
Inbreeding, AD and cognitive function
Although genetic factors have been shown to play an important role in the 
pathogenesis of late onset diseases such as AD, the genetic background of such 
disorders is poorly understood. There is some evidence that recessive or partially 
recessive variants might be implicated in late onset disorders (45). Such variants 
might escape strong selective constraints because they only have detrimental effects 
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during post-reproductive life (45). The mutation-accumulation hypothesis predicts 
that these alleles accumulate in the genome, contributing to aging and related 
disorders (46). This is in line with the increase in the genetic variance observed for 
several late onset disorders (45). 
There is evidence that inbreeding has an impact in late onset diseases such 
as hypertension (47, 48). Inbreeding increases the genetic homozygosity and thus 
enriches the genome of individuals with recessive variants (49). For AD, the evidence 
is scarce. Only one study has reported a higher prevalence of AD associated with 
inbreeding (50). Furthermore, mutations in 3 genes that cause early onset AD are 
clearly dominant (29). However, these mutations have a minor contribution to the 
total burden of the disease in the general population (51). Thus, it is likely that other 
genetic variants with less strong effects on the fi tness of individuals may be part of 
the genetic background for late onset AD.
Studies of inbreeding and cognitive function date back to as early as 1978 (52). 
Morton showed that inbreeding had detrimental effects on cognitive performance. 
In addition he showed that these effects were entirely due to recessive variants. 
In chapter 4 of this thesis, the effects of inbreeding on cognitive function in a 
sample of 2575 subjects from the GRIP population were investigated. Although 
the percentage of inbred participants in the GRIP population is high (75%), the 
inbreeding coeffi cients were on average low (mean value 0.006; lower than the 
value corresponding to a second-cousin marriage: 0.02). In the GRIP population, 
inbreeding was associated with lower visuospatial abilities and executive function. 
The effect was very small, but the fi ndings suggest that inbreeding contributes to the 
variation in general cognitive function in adults. Furthermore, the results demonstrate 
that the GRIP population may be a useful setting in which to fi nd rare recessive 
variants associated with late onset AD.
POWER OF ASSOCIATION STUDIES IN ERF 
A family-based study was conducted in the GRIP population. The Erasmus 
Rucphen Family (ERF) study was designed to fi nd susceptibility genes associated 
with quantitative traits related to complex diseases. The ERF study includes 2996 
participants belonging to 22 5-generation families, selected on the basis of the 
number of sibs (at least 5) in the second generation (5). This is the setting for the 
genetic epidemiological studies to search for genes implicated in cognitive function 
described in this thesis. One of the important questions to be addressed is: How 
powerful is the ERF study to detect genetic variants with small phenotypic effects? 
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Several genes have been genotyped in approximately 1000 participants of the 
ERF study. Preliminary power studies have shown that this sample has about 80% of 
the power required to detect a candidate polymorphism explaining as little as 1% of a 
trait’s variation at the nominal signifi cance level of 0.05. In this thesis, the associations 
between cognitive functioning and the APOE gene were investigated. In the study 
described in chapter 5, the APOE*4 variant was associated with specifi c cognitive 
domains, contributing to less than 2% of the variance of those domains, which was in 
line with previous studies (42, 53). This provides an empirical proof of the high power 
of our study sample to detect gene variants with modest effects on phenotype.
FUTURE RESEARCH
In the ERF study, extensive phenotypic information has been gathered for 
2996 subjects belonging to 22 extended pedigrees. In addition, genotyping of 
approximately 6000 SNPs (1 SNP every 0.5 cM on average) is on-going. This 
tremendous amount of information represents a methodological and computational 
challenge. It is also not yet quite clear what are the most powerful analytical 
methods in the setting of the ERF study.
The most interesting and powerful approach is perhaps Genome Wide 
Association (GWA) analysis. As demonstrated in this thesis, the GRIP population 
is a young genetically isolated population that is representative of both young 
isolates, and the general Caucasian population. We expect that common variants 
found in relation to cognitive function in the GRIP population will also have a role 
in determining cognitive ability in other populations. We have also shown that the 
ERF study is suffi ciently powerful to detect small genetic effects such as those of the 
APOE gene on specifi c cognitive domains. It is likely that other loci are implicated 
in cognitive function, as this gene only explained a small proportion of the variance 
of the cognitive domains. In addition, in the GRIP population there is moderate LD 
between genetic markers. This improves the marker coverage of the genome in ERF 
participants.
It may be expected, however, that there are also rare variants affecting cognitive 
function in the GRIP population. Under this assumption, linkage analysis should be 
a powerful method in the ERF study. The ERF families were selected based on large 
sibships that are critical for genome-wide linkage analysis. For cognitive function, 
inbreeding was associated with reduced executive function and visuospatial abilities 
(chapter 4). Therefore, homozygosity mapping may be an interesting approach to 
identify genetic variants associated with specifi c cognitive functions. 
Luba bw.indd   106 30-08-2006   17:44:56
General discussion 107
However, the same strict criteria employed for both association and linkage 
studies need to be applied to the ERF study to reduce both the type-1 and -2 errors 
associated with linkage and association studies. There are major methodological 
challenges, including the defi nition of phenotypes, to be overcome ahead of 
performing genome-wide analyses in the ERF study. The fi ndings presented in this 
thesis indicate that specifi c cognitive domains will be suited to genetic analysis, 
especially in the context of AD. Memory and executive function, for example, might 
be valuable endophenotypes for AD in the ERF study, as shown by the signifi cant 
effects of APOE*4, the well-known risk factor for AD, on these 2 cognitive domains. 
In addition, for both memory and executive function the heritability estimates were 
relatively high. Phenotypic defi nition with other tools such as neuroimaging will also 
help to identify better endophenotypes, as well as select subjects at risk for late AD. 
The work presented in this thesis has provided the foundation upon which to 
construct further studies aimed at elucidating the genetics of cognitive function as 
well as that of onset AD. 
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Alzheimer’s disease (AD) is the primary cause of dementia in Western societies, 
affecting approximately 30% of the population aged 90 years or over. Despite the 
huge effort in the scientifi c community to identify the genes involved in AD, the 
genetics of late onset AD are largely unknown. Intermediate phenotypes of AD 
(endophenotypes) may help to identify genetic and non-genetic modifi ers of the 
disease. In this thesis we aimed to identify genetic determinants of cognitive traits 
that are used as intermediate phenotypes for AD in a young genetically isolated 
population in the Southwest of The Netherlands. The research was performed as part 
of the Genetic Research in Isolated Populations (GRIP) program.
In chapter 1, the literature of the genetics of AD and Parkinson’s disease (PD) 
was reviewed in light of the current hypotheses available to explain the genetic 
background of complex disorders: common diseases/common variants and common 
diseases/rare variants. Several strategies to increase the power of genetic studies of 
neurodegenerative disorders were also delineated. 
In chapter 2 the aims and general outline of the research described in this thesis 
are presented.
In chapter 3, founder and drift effects on the GRIP population were examined. 
A large extended pedigree, including 9800 individuals derived from the GRIP 
population, was used to simulate the drift and founder effects. We found that only 
variants attaining initial frequencies equal or lower than 1% will be subjected to drift 
and founder effects, with a high probability of loss and a reduced chance of fi xation. 
To provide empirical confi rmation of the simulated data, the expected heterozygosity 
and mean number of alleles of 592 microsatellite markers from 58 subjects from 
this population were estimated. These parameters were compared with those from 
samples with a different demographic history, namely the CEPH families (general 
population), Icelandic pedigrees (old and large isolated population) and the Talana 
(a sub-isolate with strong founder effects). We observed a lower mean heterozygosity 
and a lower number of alleles in the GRIP population than in the CEPH families 
(general population) and the Icelandic population, but higher than in the Talana 
population. We concluded that the fl uctuations in the genetic pool of the GRIP 
population have occurred due to genetic drift and founder effects, but that these 
effects have only had an impact for rare genetic variants.
In this thesis, the genetics of cognitive traits that are potential endophenotypes 
for AD was examined. In chapter 4, the heritability of specifi c cognitive domains, 
as assessed by standard neuropsychological tests, was estimated in participants 
from a family-based study (The Erasmus Rucphen Family (ERF) study) in the GRIP 
population. The effects of inbreeding on cognitive variation were also examined, 
along with sex- and age-specifi c genetic effects on the phenotypic expression of 
cognitive function. The heritability estimates varied from 10% to 30% for memory-
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related traits, while for executive function the estimate was 36%. Inbreeding 
was associated with worse executive function and reduced visuospatial abilities. 
This analysis also showed that age-specifi c effects might account for age-related 
differences in psychomotor speed and susceptibility to interference. In contrast, there 
was no evidence for sex-specifi c genetic effects on cognitive function. These fi ndings 
suggest that the contribution of genetic factors to the variation in cognitive function 
is domain-specifi c. Furthermore, the signifi cant effects of inbreeding indicate that 
recessive variants may, at least partially, determine the genetic make-up of cognitive 
function.
In chapter 5, we studied the relationship between the APOE gene and cognitive 
function to examine the cognitive profi le associated with the APOE*4 allele in 
non-demented subjects. In addition, we evaluated whether age and sex modulated 
the effect of this genetic variant on the cognitive domains. Carriers of at least one 
APOE*4 allele had worse cognitive performance than non-carriers in short-term 
memory, cognitive fl exibility and susceptibility to interference. These effects were 
modulated by both age and gender, as we observed that the effect was stronger in 
those 50 years and older and also in women. The signifi cant associations between 
the APOE*4 allele and memory and executive function suggests that these cognitive 
tests may be markers of early changes in cognition.
In chapter 6, the association between blood pressure, atherosclerosis and 
polymorphisms in the angiotensinogen (AGT), angiotensin II type 1 receptor (AT1R), 
the α-adducin 1 (AAD1) and the G-protein β-3 subunit (GNβ3) genes were evaluated 
in relation to cognitive function. We found adverse effects of blood pressure and 
atherosclerosis on cognitive tests, mainly with those tests that evaluate executive 
function. The effect of the angiotensinogen AGT M235T, the AT1R C573T, the AAD1 
G460W and the GNβ3 rs2301339 polymorphisms on the cognitive tests were also 
evaluated. There was a signifi cant association between the AGT 235T allele with a 
better performance in the recognition task. In contrast, lower cognitive performance 
in phonological fl uency in carriers of the AAD1 460W allele was found. In addition, 
a worse performance in the tests that evaluate susceptibility to interference, with 
carriers of the GNβ3 G allele was observed. The joint effect of the risk alleles of 
the four genes was also evaluated. Interestingly, worse performance in all cognitive 
tests with increasing number of risk alleles was observed, although it was signifi cant 
only for learning and susceptibility to interference. There were no major differences 
in the stratifi ed age-analysis. Our results confi rm the substantial role of vascular 
factors in reduced performance in cognitive function. In addition, genes underlying 
the variation in blood pressure also contribute to the variation in cognition. The 
association of the AGT 235T allele with better performance in recognition suggests 
that angiotensinogen might have pleiotropic effects in brain. 
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The results of this thesis underscore the value of the GRIP population as a 
powerful setting to do genetic research. Future genetic studies of cognitive function 
in the setting of the ERF study are also promising.
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De ziekte van Alzheimer (Alzheimer’s Disease, AD) is de meest voorkomende 
oorzaak van dementie in de Westerse wereld. Circa 30% van de bevolking van 90 
jaar en ouder lijdt hieraan. Ondanks grote inspanningen binnen de wetenschap om 
genen te identifi ceren die betrokken zijn bij AD, blijven de genetische aspecten 
van de zgn. “late onset AD” grotendeels onbekend. Intermediaire phenotypes van 
AD (endophenotypes) kunnen mogelijk eraan bijdragen om genetische en non-
genetische factoren te identifi ceren, die de ziekte kunnen beïnvloeden. Het doel 
van dit proefschrift is het identifi ceren van genetische determinanten van cognitie, 
die gebruikt worden als intermediaire phenotypes van AD in een jonge, genetisch 
geïsoleerde populatie in het Zuid-Westen van Nederland. Het onderzoek maakt deel 
uit van het GRIP programma (Genetic Research in Isolated Populations).
In hoofdstuk 1, wordt literatuur over de genetica van AD en de ziekte 
van Parkinson (Parkinson’s Disease, PD) beschreven in het kader van de 
huidige hypotheses over de genetische achtergrond van complexe ziektes: veel 
voorkomende/zeldzame varianten van algemeen voorkomende ziektes. Verscheidene 
methoden om de “power” van genetische studies over neurodegeneratieve 
afwijkingen te vergroten worden ook besproken.
In hoofdstuk 2 worden het doel en de algemene opzet van het in dit 
proefschrift beschreven onderzoek uiteengezet.
In hoofdstuk 3 worden “founder” en “drift” effecten binnen de GRIP populatie 
bestudeerd. Een grote en uitgebreide stamboom bestaande uit 9800 personen, 
afkomstig uit de GRIP populatie, is gebruikt om deze “founder” en “drift”effecten 
te simuleren. Wij vonden dat alleen varianten met een initiële frequentie van 1% 
of minder onderhevig zijn aan deze effecten, met een grote kans op verlies en 
een verminderde kans op fi xatie. Om empirische bevestiging te verkrijgen van de 
bevindingen van de gesimuleerde data, zijn de verwachte graad van heterozygotie 
en het gemiddelde aantal allelen van 592 “microsatellite” markers in 58 personen 
uit deze populatie geschat. Deze data is vergeleken met data van personen met 
een andere demografi sche achtergrond, afkomstig van de CEPH families (algemene 
bevolking), uit IJslandse stambomen (oude en grote genetisch geïsoleerde populatie) 
en van de Talana populatie (een sub-isolaat met sterke “founder” effecten). Wij 
vonden een lagere gemiddelde heterozygotie en een kleiner aantal allelen in de 
GRIP populatie dan in de CEPH families (algemene bevolking) en de IJslandse 
populatie, maar daarentegen een hoger aantal dan in de Talana populatie. Wij 
concluderen dat fl uctuaties in de genetische “pool” van de GRIP populatie hebben 
plaatsgevonden door genetische “drift” en “founder” effecten, maar dat deze effecten 
alleen de zeldzame genetische varianten hebben beïnvloed.
In dit proefschrift zijn genetische determinanten van cognitie bestudeerd 
die potentiële endophenotypes vormen van AD. In hoofdstuk 4 is de 
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erfelijkheid van bepaalde cognitieve domeinen, beoordeeld middels standaard 
neuropsychologische testen, geschat bij deelnemers aan een familie-onderzoek 
(ERF Studie, Erasmus Rucphen Familie Studie) binnen de GRIP populatie. De 
effecten van bloedverwantschap tussen ouders op variatie in cognitie zijn ook 
bestudeerd, tezamen met geslachts- en leeftijdsspecifi eke genetische effecten op 
phenotypische expressie van cognitieve functie. Schattingen van de erfelijkheid 
variëren van 10 tot 30% voor geheugen gerelateerde eigenschappen, terwijl voor 
uitvoerende functies de schatting 36% was. Bloedverwantschap tussen ouders was 
geassocieerd met verslechterde uitvoerende functies en verminderde ruimtelijke en 
gezichtsfuncties. Deze analyse toonde ook dat leeftijdsspecifi eke effecten mogelijk 
leeftijdsgerelateerde verschillen in psychomotorische snelheid en vatbaarheid voor 
afl eiding (“interference”) kunnen verklaren. Daarentegen was er geen bewijs voor 
geslachtsspecifi eke genetische effecten op cognitie. Deze bevindingen suggereren 
dat de bijdrage van genetische factoren aan de variatie in cognitieve functie 
domein-specifi ek is. Voorts geven de signifi cante effecten van bloedverwantschap 
tussen ouders aan dat recessieve varianten, ten minste voor een deel, mogelijk de 
genetische basis van cognitieve functie bepalen.
In hoofdstuk 5 hebben wij de relatie tussen het APOE gen en cognitieve functie 
bestudeerd teneinde het cognitieve profi el, geassocieerd met het APOE*4 allel, in 
niet-dementerende personen te onderzoeken. Voorts hebben wij onderzocht of 
leeftijd en geslacht het effect van deze genetische variant op cognitieve domeinen 
beïnvloedt. Dragers van ten minste één APOE*4 allel hadden een verminderde 
cognitieve prestatie t.o.v. niet-dragers wat betreft korte termijn geheugen, mentale 
fl exibiliteit en vatbaarheid voor afl eiding. Deze effecten werden beïnvloed door 
zowel leeftijd als geslacht, daar wij zagen dat het effect sterker was bij hen die 50 
jaar of ouder waren, alsmede bij vrouwen. De signifi cante associaties tussen het 
APOE*4 allel en geheugen en uitvoerende functies kunnen erop wijzen dat deze 
cognitieve testen mogelijk markers zijn van vroege veranderingen in cognitie.
In hoofdstuk 6 wordt de associatie tussen zowel bloeddruk, atherosclerose 
en polymorphismen in het angiotensinogeen (AGT) gen, het angiotensine II 
type 1 receptor (AT1R) gen, het α-adducin 1 (AAD1) gen en het G-protein β-3 
subunit (GNβ3) gen in relatie tot cognitieve functie bestudeerd. Wij vonden een 
negatief effect van bloeddruk en atherosclerose op cognitieve tests, vnl. op die 
tests die uitvoerende functies evalueren. Het effect van de AGT M235T, AT1R 
C573T, AAD1 G460W en GNβ-3 rs2301339 polymorphismen op cognitieve tests 
werd ook bestudeerd. Er was een signifi cante associatie tussen het AGT 235T allel 
en een betere prestatie bij herkenning. In tegenstelling werd een verminderde 
cognitieve prestatie in phonemische vloeiendheid bij dragers van het AAD1 460W 
allel gevonden. Daarnaast observeerden wij bij dragers van het GNβ3 G allel een 
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slechtere prestatie in tests die de vatbaarheid voor afl eiding beoordelen. Ook werd 
het effect van een combinatie van de risico-allelen van deze vier genen geëvalueerd. 
Het was daarbij interessant dat een verslechterde prestatie bij alle cognitieve tests 
werd waargenomen bij een toenemend aantal risico allelen, alhoewel deze bevinding 
alleen voor leervermogen en vatbaarheid voor afl eiding signifi cant was. Er waren 
geen grote verschillen in analyses in verschillende leeftijdsgroepen. Onze resultaten 
bevestigen de grote rol van vasculaire factoren bij verminderde prestatie op cognitief 
gebied. Voorts dragen genen die variatie in bloeddruk beïnvloeden ook bij aan de 
variatie in cognitie. De associatie van het AGT 235T allel en verbeterde herkenning 
duidt mogelijk op de pleiotrope effecten op de hersenen die angiotensinogeen zou 
kunnen hebben.
De resultaten van dit proefschrift benadrukken het belang van de GRIP populatie 
als een krachtige opzet om genetisch onderzoek te verrichten. Toekomstige studies 
van cognitieve functie binnen de ERF studie zijn ook veelbelovend.
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La enfermedad de Alzheimer es la primera causa de demencia en sociedades 
occidentales afectando aproximadamente un 30% de la poblacion mayor de 90 años 
de edad. A pesar del enorme esfuerzo de la comunidad científi ca para identifi car el 
component genético de de la enfermedad de Alzheimer, los genes responsables de 
las formas más comunes esta patología no han sido completamente determinados. 
Fenotipos intermedios de la enfermedad de Alzheimer (endofenotipos) podrían 
ayudar en la identifi cación de determinantes genéticos y no genéticos de este 
desorden neurodegenerativo. La función cognitiva, entre otros, es un potencial 
endofenotipo de la enfermedad de Alzheimer. Esta tesis presenta estudios realizados 
para identifi car determinantes genéticos de la función cognitiva en una poblacion 
genéticamente aislada en el suroeste de Holanda. Este trabajo hace parte del 
programa llamado “Genetic Research in Isolated Populations (GRIP)”. 
En el capítulo 1, una revisión de la literatura acerca de la genética de la 
enfermedad de Alzheimer y la enfermedad de Parkinson es presentada a la luz de 
las hipótesis mas aceptadas acerca de la variación genética de las enfermedades 
complejas. Además, algunas estrategias para aumentar el poder de los estudios 
genéticos de enfermedades neurodegenerativas es delineada.
En el capítulo 2, el objetivo general de esta tesis es presentado. 
En el capítulo 3, los efectos de deriva genética (genetic drift/ founder effects) 
en la poblacion de GRIP fueron investigados. Para ello, una familia extendida que 
incluyó 9800 individuos fue usada para simular los efectos de deriva genética. 
En este estudio se observó que las frecuencias alélicas iguales a 1% o menores, 
están sujetas a deriva genética, con una alta probabilidad de ser eliminadas 
de la población. Para confi rmar los resultados del estudio de simulación, la 
Heterozigosidad Esperada (EH) y la diversidad alélica fueron estimados usando 592 
microsatelites (short-tanden repeats) en una muestra de 58 personas de la población 
de GRIP. Estos parametros (EH y numero promedio de alelos) fueron comparados 
con los obtenidos de poblaciones con una historia demográfi ca diferente: familias 
CEPH (muestra de una población general), familias de Islandia (representativas 
de una población genéticamente aislada y antigua) y familias de la población de 
Talana (representativas de una población aislada sometida a gran deriva genética). 
En este estudio se observó que la EH y numero promedio de alelos en la población 
de GRIP es menor respecto de las familias de CEPH y Islandia, pero mayor que en 
la población de Talana. Nosotros concluimos que ha habido fl uctuaciones en el 
acervo genético de la población de GRIP debido a deriva genética, pero que estas 
fl uctuaciones solo tienen impacto en variantes alélicas que son raras en la población 
(frequencias ≤ 1%).
En esta tesis, la genética de pruebas cognitivas (potentiales endofenotipos para 
la enfermedad de Alzheimer) fue investidada. En el capítulo 4, la heredabilidad 
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(heritability) de dominios cognitivos específi cos fue estimada en participantes del 
estudio de ERF (Erasmus Rucphen family-ERF) en la población de GRIP. Además, los 
effectos de consaguidad (inbreeding) y la heredabilidad específi ca de sexo y edad 
en la variación de la función cognitiva de los participantes de ERF fueron estimados. 
La heredabilidad estimada fl uctuó entre 10 a 30% en pruebas cognitivas relacionadas 
con memoria, mientras que los estimados de heredabilidad para las pruebas 
relacionadas con función ejecutiva fue en promedio 36%. Además, se observo que el 
grado de consaguinidad entre los padres de un individuo esta asociado a un menor 
rendimiento en pruebas cognitivas que evaluan función ejecutiva y habilidades 
visoespaciales. Este análisis también mostró que la expresión de genes específi ca 
por edad, podría explicar differencias en “rapidez psicomotora” y susceptibilidad 
a la interferencia”. Por otro lado, no encontramos evidencia de que las diferencias 
en la variación en función cognitiva entre mujeres y hombres sea explicada por 
differencias en la expression de genes. Los resultados sugieren que la magnitud de la 
expresión de genes que modulan cognición varía de acuerdo a dominios especifi cos. 
Además, las asociación de consaguinidad con ciertos dominios cognitivos parece 
indicar que parte del material genético que modula cognición esta constituido por 
variantes que actuan de manera recesiva.
En el capítulo 5, la relación entre el gen que codifi ca para la apolipoproteina 
E (APOE) y función cognitiva fue investigada, para examinar el perfi l cognitivo 
asociado con el alelo APOE*4. También investigamos si la edad y el género modulan 
los efectos de este variante genético en determinados dominios cognitivos. Se 
observó que personas con una o dos copias del alelo APOE*4 presentaron un 
menor rendimiento en las pruebas cognitivas que evaluan “memoria de corto plazo”, 
“fl exibilidad cognitiva” y “susceptibilidad a la interferencia” respecto de las personas 
que no son portadoras del alelo APOE*4. Estos efectos son modulados por edad y 
sexo, dado que el efecto fue signifi cativo únicamente en el grupo de sujetos mayores 
de 50 años o en mujeres. Estos efectos estadísticamente signifi cativos entre el 
variante APOE*4 y función cognitiva sugieren que estas pruebas cognitivas podrían 
ser macadores tempranos de deterioro cognitivo asociado con la enfermedad de 
Alzheimer.
En el capítulo 6, la asociación entre presion arterial ateroesclerosis y 
polimorfi smos en los genes angiotensinogeno (AGT), receptor tipo 1 de la 
angiotensina II (AT1R), alfa aducina 1(AAD1) y subunidad 3 de la proteína G 
(GNβ3) fueron evaluados en relación con la función cognitiva. Se observaron 
effectos adversos de la presión arterial (sistólica y diastólica) sobre función cognitiva 
particularmente en las pruebas que evaluan función ejecutiva. Además, se evaluó el 
efecto sobre la función cognitiva de los siguientes polimorfi smos: AGT M235T, AT1R 
C535T AAD1 G460W y GNβ3 rs2301339. Encontramos una asociación signifi cativa 
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entre el alelo T del gen AGT con un mejor rendimiento en la prueba cognitiva 
que evalua “reconocimiento”. Por otro lado, observamos un menor rendimiento 
en la prueba que evalua “fl uencia fonologica” en portadores del alelo 460W del 
gen AAD1, al igual que menor rendimiento la prueba que evalua “susceptibilidad 
a la interferencia” en portadores del alelo G del gen GNβ3. También estudiamos 
el effecto combinado de los alelos de riesgo de los cuatro genes asociados con 
presion arterial sobre la función cognitiva. Un menor rendimiento fue observado en 
todas las pruebas cognitivas por aumento en el numero de alelos de riesgo, aunque 
solo se alcanzó signifi cancia estadística en las pruebas que evaluan “aprendizaje” y 
“susceptibilidad a la interferencia”. No se observó ninguna diferencia en el análisis 
estratifi cado por edad. Nuestros resultados confi rman el efecto substancial de 
factores vaculares en la disminución de la función cognitiva. Además, los genes 
que infl uencian presión arterial contribuyen también a la variación en la función 
cognitiva. La asociación del gen de AGT con un mejor rendimiento en la prueba que 
evalua “reconocimiento” sugiere que este gen podría tener efectos pleiotrópicos en 
el cerebro.
Los resultados de esta tesis subrayan el valor de la poblacion de GRIP para 
realizar estudios genéticos. Futuros estudios en el contexto del estudio de ERF son 
igualmente prometedores en la busqueda de genes involucrados en la función 
cognitiva y la enfermedad de Alzheimer.
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